Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”
English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry Junichi Iga, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Ken Inada, Dep...
Saved in:
| Published in | Neuropsychopharmacology reports Vol. 41; no. 3; pp. 266 - 324 |
|---|---|
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.09.2021
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry Junichi Iga, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Ken Inada, Department of Psychiatry, Tokyo Women’s Medical University Taro Kishi, Department of Psychiatry, Fujita Health University School of Medicine Hiroshi Kimura, Department of Psychiatry, International University of Health and Welfare/Gakuji-kai Kimura Hospital Yuki Matsuda, Department of Psychiatry, Jikei University School of Medicine Nobumi Miyake, Department of Neuropsychiatry, St. Marianna University School of Medicine Kiyotaka Nemoto, Department of Psychiatry, Faculty of Medicine, University of Tsukuba Shusuke Numata, Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University Shinichiro Ochi, Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine Hideki Sato, National Center Hospital, National Center of Neurology and Psychiatry Seiichiro Tarutani, Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine English translation team: (COI as of 2018-2020) Ryota Hashimoto: Received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Tobacco Inc., and Takeda Pharmaceutical Company Ltd.; rewards for lectures from Takeda Pharmaceutical Company Ltd., Lundbeck Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., and Mochida Pharmaceutical.Co., Ltd.; manuscript fees for writing from Dainippon Sumitomo Pharma Co., Ltd. Junchi Iga: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Pharmaceutical Industry Co. Ltd., Shionogi & Co. Ltd., Mochida Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mylan Inc., Sawai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., Viatris Inc., and Yoshitomiyakuhin Co. Ken Inada: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Taro Kishi: Received speaker’s honoraria from Sumitomo Dainippon, Otsuka, Eisai, Daiichi Sankyo, Janssen, Takeda, Kyowa, Kissei, Meiji, Pfizer, Mochida, Eli Lilly, MSD, Janssen, and Tanabe-Mitsubishi (Yoshitomi); as well as research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research, and Fujita Health University School of Medicine. Before reading this guideline (For experts, patients, families, and supporters) This guideline was written for specialists in the treatment of schizophrenia, but patients, as well as their families and supporters, may also use this guideline. [...]a very simple explanation will first be given on the aims of this guideline. [...]one may have the impression from reading the individual texts that it is recommended to treat schizophrenia with pharmacological therapy alone, or that pharmacological therapy has a larger effect than other therapies. [...]the available drugs and their administration and the medical system can vary between Japan and other countries. [...]a clinical guideline that is aligned with the medical circumstances in Japan was needed. |
|---|---|
| AbstractList | English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry Junichi Iga, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Ken Inada, Department of Psychiatry, Tokyo Women’s Medical University Taro Kishi, Department of Psychiatry, Fujita Health University School of Medicine Hiroshi Kimura, Department of Psychiatry, International University of Health and Welfare/Gakuji-kai Kimura Hospital Yuki Matsuda, Department of Psychiatry, Jikei University School of Medicine Nobumi Miyake, Department of Neuropsychiatry, St. Marianna University School of Medicine Kiyotaka Nemoto, Department of Psychiatry, Faculty of Medicine, University of Tsukuba Shusuke Numata, Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University Shinichiro Ochi, Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine Hideki Sato, National Center Hospital, National Center of Neurology and Psychiatry Seiichiro Tarutani, Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine English translation team: (COI as of 2018-2020) Ryota Hashimoto: Received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Tobacco Inc., and Takeda Pharmaceutical Company Ltd.; rewards for lectures from Takeda Pharmaceutical Company Ltd., Lundbeck Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., and Mochida Pharmaceutical.Co., Ltd.; manuscript fees for writing from Dainippon Sumitomo Pharma Co., Ltd. Junchi Iga: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Pharmaceutical Industry Co. Ltd., Shionogi & Co. Ltd., Mochida Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mylan Inc., Sawai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., Viatris Inc., and Yoshitomiyakuhin Co. Ken Inada: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Inc., Meiji Seika Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., and Yoshitomiyakuhin Co. Taro Kishi: Received speaker’s honoraria from Sumitomo Dainippon, Otsuka, Eisai, Daiichi Sankyo, Janssen, Takeda, Kyowa, Kissei, Meiji, Pfizer, Mochida, Eli Lilly, MSD, Janssen, and Tanabe-Mitsubishi (Yoshitomi); as well as research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research, and Fujita Health University School of Medicine. Before reading this guideline (For experts, patients, families, and supporters) This guideline was written for specialists in the treatment of schizophrenia, but patients, as well as their families and supporters, may also use this guideline. [...]a very simple explanation will first be given on the aims of this guideline. [...]one may have the impression from reading the individual texts that it is recommended to treat schizophrenia with pharmacological therapy alone, or that pharmacological therapy has a larger effect than other therapies. [...]the available drugs and their administration and the medical system can vary between Japan and other countries. [...]a clinical guideline that is aligned with the medical circumstances in Japan was needed. |
| Author | Japanese Society of Neuropsychopharmacology |
| Author_xml | – sequence: 1 email: jsnp@aeplan.co.jp |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34390232$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQgC1UREvphQdAkbigSlv8F8fhUAlVpRRVpaJF4mY5znjjVTYO9gYUTn0QeLk-Cd5NKS0HDpZHM58_jcbzFG11vgOEnhN8QDCmr7s-0ANCSckeoR2aF3xGCvZl6168jfZiXOAErw_jT9A246xMId1B7oPudQcRsktvHKzGzNvsHIbg-ziaxveNDkttfOvn45vs5vrnyeBqaF0HmfUhu_hbdka32VUDQfcbyaVp3I_0PkDn9M31r2fosdVthL3bexd9fnd8dfR-dvbx5PTo7dnMCMzZjAkqTJ1XBXAK2BhTiJqkUIKRsgYpmZFUFIIJCxQsKbkujBamtFYSJmu2i04nb-31QvXBLXUYlddObRI-zJUOK2daUHXBLc8FJ6wsuKyM5BXUyaarMrcVlMl1OLn6oVpCbaBbBd0-kD6sdK5Rc_9NSU4IoyQJXt0Kgv86QFyppYsG2jbN3A9R0VwQXmKBcUJf_oMu_BC6NKo1JUlOOcsTtT9RJvgYA9i7ZghW64VQ64VQm4VI8Iv77d-hf74_AWQCvrsWxv-o1PnFJzpJfwOcV8Xm |
| CitedBy_id | crossref_primary_10_1016_j_schres_2023_01_019 crossref_primary_10_3389_fpsyt_2023_1331356 crossref_primary_10_1017_S204579602200066X crossref_primary_10_1111_pcn_13342 crossref_primary_10_1016_j_ajp_2024_104047 crossref_primary_10_1016_j_schres_2023_03_008 crossref_primary_10_1007_s40263_023_01054_z crossref_primary_10_1016_j_psychres_2024_115810 crossref_primary_10_1097_JCP_0000000000001604 crossref_primary_10_1093_ijnp_pyac036 crossref_primary_10_1007_s12325_022_02252_9 crossref_primary_10_1016_j_sleep_2021_11_005 crossref_primary_10_1186_s12888_023_05176_y crossref_primary_10_1002_npr2_12385 crossref_primary_10_1097_JCP_0000000000001841 crossref_primary_10_3390_medicina58111584 crossref_primary_10_1192_bjo_2022_630 crossref_primary_10_1038_s41537_023_00407_3 crossref_primary_10_1002_14651858_CD014384_pub2 crossref_primary_10_1002_npr2_12245 crossref_primary_10_1002_npr2_12300 crossref_primary_10_1111_pcn_13455 crossref_primary_10_1111_pcn_13355 crossref_primary_10_1111_pcn_13432 crossref_primary_10_9758_cpn_2023_21_2_332 crossref_primary_10_1016_j_psycom_2024_100158 crossref_primary_10_1186_s12888_024_05816_x crossref_primary_10_11642_kyushuneurop_68_1_9 crossref_primary_10_1093_ijnp_pyad037 crossref_primary_10_1371_journal_pone_0287122 crossref_primary_10_2147_NDT_S402945 crossref_primary_10_1111_pcn_13578 crossref_primary_10_1007_s10578_022_01330_x crossref_primary_10_1016_j_ajp_2022_103007 crossref_primary_10_1002_npr2_12293 crossref_primary_10_2147_NDT_S390482 crossref_primary_10_1093_ijnp_pyac044 crossref_primary_10_1093_schbul_sbae098 crossref_primary_10_1080_08039488_2023_2277820 crossref_primary_10_1186_s12888_023_05474_5 crossref_primary_10_1248_yakushi_23_00105 crossref_primary_10_1080_13543784_2023_2291470 crossref_primary_10_1177_20451253231168788 crossref_primary_10_1007_s44211_024_00619_2 crossref_primary_10_1016_j_jpsychires_2023_10_055 crossref_primary_10_1186_s12888_023_05240_7 crossref_primary_10_1186_s12991_022_00429_8 crossref_primary_10_1002_npr2_12378 |
| Cites_doi | 10.1097/00131746-200603000-00005 10.1046/j.1440-1819.2001.00882.x 10.1097/01.pra.0000369974.18274.e2 10.1001/jamapsychiatry.2013.149 10.1016/j.euroneuro.2008.04.012 10.1176/appi.ajp.163.12.2096 10.1017/S1461145712001277 10.1176/appi.ps.52.8.1095 10.4088/JCP.12m07642 10.4088/JCP.v68n0104 10.1016/S0893-133X(98)00090-6 10.1097/jcp.0b013e31815abf34 10.1097/00004714-199904000-00009 10.1034/j.1600-0447.2000.101003218.x 10.1017/S0033291798008186 10.1111/j.1440-1819.2004.01269.x 10.1097/00124509-200206000-00005 10.1016/j.eurpsy.2004.07.001 10.2165/00023210-200923070-00006 10.1176/ajp.155.4.499 10.1176/ajp.155.7.914 10.1016/j.schres.2012.02.021 10.1016/S0140-6736(12)60239-6 10.1097/01.jcp.0000084027.22282.16 10.4088/JCP.v69n0509 10.1176/appi.ajp.2008.08050756 10.1097/01.pra.0000336753.11943.7c 10.1038/npp.1993.54 10.1017/S146114570500516X 10.1097/00004850-199705000-00001 10.1007/s00213-003-1506-y 10.1111/j.1600-0447.1995.tb09572.x 10.3109/15622975.2012.696143 10.3928/0048-5713-20000501-10 10.1176/appi.ajp.2013.12010127 10.1002/gps.508 10.1017/S1461145703003651 10.1093/schbul/sbn135 10.1001/archpsyc.1988.01800330013001 10.1097/01.jcp.0000195109.01898.5e 10.4088/JCP.v68n0601 10.1177/0269881111405555 10.1097/00004714-200306000-00002 10.1176/appi.ajp.158.7.1149 10.4088/JCP.v69n0702 10.1016/j.eurpsy.2006.03.005 10.1176/ajp.2007.164.7.1050 10.1192/bjp.166.6.712 10.4088/JCP.v69n0505 10.1176/ajp.2006.163.12.2072 10.1016/j.psychres.2009.03.030 10.1016/j.euroneuro.2004.03.005 10.1016/j.schres.2007.02.009 10.1097/YCO.0b013e32832a16da 10.1016/S0924-977X(02)00127-X 10.1176/jnp.23.2.jnp223 10.1093/schbul/sbm134 10.1016/j.schres.2014.07.015 10.1016/j.schres.2013.02.005 10.4088/JCP.v64n1110 10.1097/JCP.0b013e3181c9bfe6 10.1016/S0006-3223(97)00190-X 10.1192/bjp.bp.109.069328 10.1016/S0140-6736(09)60742-X 10.1016/j.biopsych.2007.04.043 10.1186/1471-244X-11-145 10.1176/ajp.145.8.993 10.1097/00124509-199906000-00004 10.1177/0269881105048902 10.1111/j.1440-1819.2009.02042.x 10.1111/j.1600-0447.2004.00450.x 10.1097/00004714-199602000-00007 10.1136/bmj.39339.448819.AE 10.1016/0893-133X(95)00069-P 10.1093/schbul/sbp116 10.1176/appi.ajp.162.5.947 10.1007/s00213-012-2838-2 10.3109/15622970802309617 10.4088/JCP.09m05785yel 10.1192/bjp.166.2.241 10.4088/JCP.v67n1004 10.1097/YIC.0b013e32834bbc0d 10.1192/bjp.188.3.255 10.1176/appi.ajp.159.2.255 10.1016/j.pnpbp.2005.10.015 10.1192/bjp.bp.108.055137 10.1176/appi.ajp.2011.10081224 10.1002/hup.1017 10.1016/j.schres.2008.02.021 10.1002/hup.1189 10.1097/00004850-200303000-00008 10.1007/s00406-004-0517-y 10.1016/0893-133X(94)00069-C 10.1001/archpsyc.1983.01790070083010 10.1176/ajp.151.6.825 10.4088/JCP.v65n0516 10.1002/hup.2270 10.1097/jcp.0b013e3180582439 10.1016/j.schres.2009.05.024 10.1176/appi.ajp.162.9.1744 10.1097/00004850-200403000-00003 10.1001/archpsyc.1988.01800330021002 10.1007/s00213-013-3241-3 10.1093/schbul/sbu030 10.1016/j.schres.2007.08.002 10.1192/bjp.bp.111.101485 10.1016/j.schres.2012.08.018 10.1111/j.1742-1241.2009.02085.x 10.1055/s-2000-8355 10.1055/s-0029-1234105 10.1176/appi.ajp.158.11.1835 10.1016/0010-440X(89)90065-5 10.1192/bjp.195.52.s63 10.1002/hup.1257 10.1016/j.psc.2012.06.007 10.1016/j.pnpbp.2010.08.017 10.2165/11598540-000000000-00000 10.1097/JCP.0b013e3182970490 10.1016/S0920-9964(01)00314-0 10.1007/s00213-003-1505-z 10.1016/0278-5846(86)90048-5 10.1007/s00213-011-2392-3 10.2165/11314280-000000000-00000 10.1016/j.pnpbp.2003.09.033 10.1017/S1355617708080090 10.1007/s00213-004-2082-5 10.4088/JCP.v65n0607 10.3371/CSRP.5.1.3 10.1097/WNF.0b013e31817c6b06 10.1001/archgenpsychiatry.2011.1532 10.1111/j.1600-0447.2004.00486.x 10.1097/JCP.0b013e3182677958 10.1001/archpsyc.1997.01830170079011 10.1176/ajp.152.4.648 10.1177/0269881109106306 10.1177/0269881105057001 10.3928/0048-5713-19910301-08 10.1097/JCP.0b013e318218dcd5 10.1080/13651500802085369 10.1055/s-2007-979481 10.4088/JCP.09m05125yel 10.1016/S0006-3223(98)00109-7 10.1007/s004060050039 10.1136/jcp.53.6.481 10.1080/10401230802017092 10.4088/JCP.08m04315 10.1097/01.jcp.0000096246.29231.73 10.1176/ajp.156.9.1374 10.1056/NEJMoa051688 10.1007/s002130051008 10.1192/bjp.bp.108.050088 10.1001/archpsyc.1971.01750170020004 10.1016/S0924-977X(96)00392-6 10.1038/npp.2009.164 10.4088/JCP.09m05274yel 10.4088/JCP.v68n0206 10.1177/0269881108096070 10.4088/JCP.v68n0709 10.1093/schbul/sbt090 10.1177/070674370705200708 10.1192/bjp.161.2.254 10.4088/JCP.09m05866yel 10.1016/j.schres.2006.09.013 10.4088/JCP.v63n0903 10.1016/S0006-3223(98)00312-6 10.1192/bjp.151.5.634 10.1016/j.pnpbp.2004.05.016 10.1111/j.1600-0447.2009.01484.x 10.1038/sj.npp.1300023 10.1038/npp.2010.111 10.1093/oxfordjournals.schbul.a033413 10.1016/j.pnpbp.2007.09.007 10.1016/j.schres.2007.10.022 10.1001/archpsyc.1989.01810100056011 10.2174/157340012798994867 10.1046/j.1440-1819.2002.00937.x 10.4088/JCP.v68n0301 10.1093/schbul/sbr004 10.1016/j.schres.2010.02.001 10.1097/yct.0b013e3181587949 10.1016/j.schres.2012.03.018 10.1016/j.schres.2011.11.021 10.1093/schbul/sbq042 10.1001/archpsyc.60.7.681 10.1016/j.schres.2006.03.037 10.1080/15622970903166312 10.1176/appi.ajp.2008.08060806 10.1037/1064-1297.15.6.563 10.3371/CSRP.4.2.3 10.1007/s00228-004-0835-z 10.1017/S0033291799001476 10.1177/070674370605100310 10.1093/schbul/21.3.431 10.1176/ajp.155.6.751 10.3109/13651500903402450 10.1136/bmj.321.7273.1371 10.1001/archpsyc.56.3.241 10.1192/bjp.174.3.238 10.1176/appi.ajp.2007.07010079 10.1002/1531-8257(199907)14:4<652::AID-MDS1015>3.0.CO;2-G 10.4088/JCP.v68n1113 10.1136/bmj.301.6756.837 10.1177/0269881110391123 10.1038/npp.2008.209 10.1016/j.pnpbp.2012.07.007 10.1056/NEJMoa1005987 10.1016/j.schres.2012.08.030 10.1192/bjp.bp.105.017020 10.1176/ajp.154.9.1248 10.1176/appi.ajp.158.6.968-a 10.1016/j.psychres.2010.11.017 10.1016/S0149-2918(03)80129-7 10.1192/bjp.173.4.325 10.1093/oxfordjournals.schbul.a033430 10.4088/JCP.v65n1207 10.4088/JCP.v65n0315 10.1111/j.1440-1614.2004.01382.x 10.1097/00131746-200607000-00004 10.1016/j.schres.2013.11.041 10.1056/NEJM197502202920803 10.1176/appi.ajp.2012.11091432 10.1016/S0920-9964(00)00135-3 10.1111/j.1472-8206.1994.tb00808.x 10.1111/j.1600-0447.2011.01792.x 10.1176/appi.ajp.2011.10060908 10.1177/0004867413488221 10.1097/00002826-199619030-00007 10.4088/JCP.v68n1120 10.1007/s00213-002-1342-5 10.2147/TCRM.S3153 10.1016/0165-1781(83)90059-8 10.1097/01.wnf.0000172994.56028.c3 10.1192/bjp.174.1.23 10.1097/JCP.0b013e31817e63a5 10.1097/00004850-200401000-00004 10.1016/j.pnpbp.2011.11.008 10.2165/00023210-200721010-00003 10.1056/NEJM199709183371202 10.1001/archpsyc.1990.01810200069010 10.1097/YIC.0b013e3280117feb 10.1016/j.schres.2007.03.029 10.2190/QPWL-14H7-HPGG-A29D 10.4088/JCP.v67n0509 10.1007/s002130050755 10.1111/j.1600-0447.1994.tb01515.x 10.1097/YIC.0b013e3282fcff2f 10.1016/0166-4328(96)00066-6 10.3310/hta7130 10.1002/hup.1056 10.1097/00004714-199106000-00022 10.1177/0269881110372548 10.1007/PL00014198 10.1136/bmj.39341.608519.BE 10.1192/bjp.145.3.304 10.1038/mp.2011.143 10.1016/S0140-6736(08)61764-X 10.1111/j.1600-0447.1988.tb06375.x 10.1097/JCP.0b013e3182488758 10.1016/S0278-5846(00)00118-4 10.2190/X0FF-VU7G-QQP7-L5V7 10.1016/j.schres.2009.05.007 10.1097/WNF.0b013e3181ee7f63 10.1038/374542a0 10.1097/00004714-199502001-00007 10.1097/01.jcp.0000115663.45074.8a 10.1016/S0006-3223(00)01026-X 10.1097/JCP.0000000000000050 10.1017/S0033291703007645 10.1016/j.eurpsy.2010.04.005 10.4088/JCP.10m06349 10.4088/JCP.v62n0204 10.1097/JCP.0b013e3181d35d6b 10.1093/schbul/sbn018 10.1097/01.jcp.0000246215.49271.b8 10.1001/jamapsychiatry.2013.19 10.3109/00048674.2011.572852 10.1016/S0924-977X(02)00155-4 10.1097/JCP.0b013e3181d2193c 10.1176/appi.ajp.161.1.116 10.1093/schbul/sbu067 10.1097/00004714-199706000-00010 10.1016/j.schres.2008.09.029 10.2165/00003088-200342070-00001 10.4088/JCP.v69n0214 10.1038/npp.2010.21 10.1007/s002139900351 10.1002/pds.3567 10.1176/appi.ajp.158.8.1305 10.1136/bmj.327.7417.708 10.1016/j.schres.2010.02.1060 10.1176/ajp.153.3.321 10.1016/j.schres.2006.05.004 10.1093/oxfordjournals.schbul.a033374 10.1016/j.schres.2006.09.027 10.3109/10401230009147094 10.1016/j.biopsych.2007.01.017 10.1016/S0735-6757(02)42249-8 10.4088/JCP.v65n1118 10.1177/0269881108089816 10.1176/appi.ajp.2014.13060787 10.1111/acps.12241 10.1097/JCP.0b013e318169d4ce 10.1016/j.schres.2009.01.002 10.1097/01.jcp.0000246211.95905.8c 10.4088/JCP.09m05154yel 10.3923/pjbs.2007.4287.4290 10.1016/0140-6736(91)90138-F 10.1176/appi.ajp.2009.09030358 10.4088/JCP.v66n0808 10.1192/bjp.149.1.42 10.1017/S1461145701002620 10.1016/S0920-9964(99)00197-8 10.1097/jcp.0b013e318160864f 10.1176/ajp.2006.163.4.743 10.1016/j.jpsychires.2012.02.013 10.1017/S1461145710000490 10.1017/S1461145703004012 10.1111/j.1600-0447.1996.tb09815.x 10.1016/S0140-6736(08)60486-9 10.1097/00004714-198912000-00003 10.1016/S0140-6736(13)60733-3 10.1097/JCP.0b013e3181db8715 10.1016/S0006-3223(99)00152-3 10.1097/00124509-199909000-00002 10.1001/archpsyc.1996.01830120020005 10.2165/11530260-000000000-00000 10.1097/00004714-200002000-00018 10.1097/01.jcp.0000117422.05703.ae 10.4088/JCP.13r08440 10.1093/schbul/sbp163 10.1016/S0016-5085(77)80141-8 10.1176/ajp.151.12.1753 10.1016/0006-3223(94)90089-2 10.1001/archpsyc.59.5.441 10.1016/j.jpsychires.2007.05.002 10.4088/JCP.09m05258gre 10.2174/157488611797579230 10.1176/ajp.2007.164.6.870 10.3109/15622975.2012.739708 10.1192/bjp.156.3.412 10.1016/0920-9964(95)00096-8 10.1017/S1461145704004262 10.1002/wps.20060 10.1097/JCP.0b013e31802dda4a 10.1097/00131746-200511001-00002 10.1001/archpsyc.1997.01830180067009 10.1016/j.schres.2012.11.006 10.4088/JCP.12m08186 10.1136/bcr.09.2011.4790 10.1016/j.schres.2011.02.011 10.1089/104454603322572697 10.1097/WNF.0b013e31825e7945 10.1016/j.biopsych.2004.06.029 10.4088/JCP.09m05699gre 10.1016/j.pnpbp.2004.11.005 10.1097/00004850-199300810-00011 10.1177/2045125311405566 10.4088/JCP.v68n0502 10.1097/00004850-199805000-00008 10.1136/bmj.298.6679.985 10.1002/gps.862 10.1016/0278-5846(95)00309-6 10.1212/WNL.40.9.1427 10.1097/00004714-199002000-00024 10.1016/j.schres.2006.09.012 10.1007/s00406-007-0739-x 10.1159/000119254 10.4088/JCP.v68n0503 10.4088/JCP.v66n0907 10.1001/archpsyc.1995.03950130029004 10.1016/j.schres.2007.03.003 10.1002/hup.477 10.1001/archpsyc.60.1.82 10.1192/bjp.188.2.122 10.1056/NEJMoa002028 10.1097/JCP.0b013e31818aaf6c 10.2165/00002018-199819010-00005 10.1093/schbul/sbs005 10.1016/j.schres.2008.09.031 10.1016/j.clinthera.2005.10.001 10.1176/ajp.156.2.294 10.2147/DMSO.S62681 10.1002/hup.514 10.1097/00004714-199302000-00004 10.4088/JCP.v69n0122e 10.1001/jama.2007.56-b 10.1590/S1516-44462006000400005 10.2165/00003088-199834030-00005 10.1016/0006-3223(90)90594-R 10.1097/JCP.0000000000000250 10.1007/BF00439271 10.1016/0278-5846(92)90059-N 10.1080/j.1440-1614.1999.00630.x 10.1093/schbul/sbs150 10.1016/j.ajem.2004.02.021 10.1017/S1092852900013407 10.1176/appi.ajp.158.11.1930-a 10.1001/archpsyc.60.12.1228 10.1016/S0006-3223(98)00291-1 10.2165/11587810-000000000-00000 10.1007/s002130050904 10.1002/hup.1272 10.1016/j.schres.2006.06.021 10.1097/00004714-200006000-00011 10.1177/070674370705200607 10.4088/JCP.08m04634 10.1176/appi.ajp.162.5.1013 10.1097/00004850-200111000-00002 10.1176/appi.ajp.160.8.1396 10.1097/00004714-200106000-00002 10.1097/00004850-200103000-00003 10.1016/j.pnpbp.2010.08.030 10.4088/JCP.v68n1207 10.1080/15622970902718782 10.1097/00004714-199010060-00002 10.1016/j.schres.2013.04.014 10.1176/appi.ajp.162.10.1888 10.1097/00002826-200603000-00002 10.1192/bjp.169.4.483 10.1089/cap.2011.0136 10.4103/0019-5545.82544 10.1097/00004714-200112000-00013 10.1016/S0165-1781(03)00107-0 10.1007/BF00215481 10.1177/026988110401800306 10.1016/0140-6736(91)90410-Q 10.1097/JCP.0b013e31827cb017 10.1007/s00406-007-0748-9 10.1093/schbul/22.3.455 10.1017/S1461145703004024 10.1001/archpsyc.63.7.721 10.1097/JCP.0b013e3182825c1e 10.1176/appi.ajp.160.11.2063 10.4088/JCP.v68n1008 10.1097/00004714-199808000-00009 10.4088/JCP.v63n1006 10.1136/bmj.38881.382755.2F 10.1192/bjp.185.1.63 10.1097/00004850-200203000-00003 10.1186/1471-244X-13-20 10.1016/j.euroneuro.2013.03.001 10.1111/j.1600-0447.2010.01608.x 10.1016/S0006-3223(01)01342-7 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology – notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | Japanese Society of Neuropsychopharmacology |
| CorporateAuthor_xml | – name: Japanese Society of Neuropsychopharmacology |
| DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS PSYQQ 7X8 5PM DOA |
| DOI | 10.1002/npr2.12193 |
| DatabaseName | Wiley Online Library Wiley Online Library Free Content Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest One Psychology ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Medicine |
| DocumentTitleAlternate | Japanese Society of Neuropsychopharmacology |
| EISSN | 2574-173X |
| EndPage | 324 |
| ExternalDocumentID | oai_doaj_org_article_d74f4564139748bc84bed7caab95fbe9 10_1002_npr2_12193 34390232 NPR212193 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Ministry of Health, Labor and Welfare, Japan |
| GroupedDBID | 0R~ 1OC 24P 7X7 8FI 8FJ AAHHS ABDBF ABUWG ACCFJ ACGFS ACXQS ADBBV ADKYN ADPDF ADZMN AEEZP AEQDE AFKRA AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BCNDV BENPR BPHCQ BVXVI CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK IAO IHR INH M~E O9- OK1 OVD OVEED PGMZT PIMPY PQQKQ PROAC PSYQQ RPM TEORI UKHRP WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION ITC 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c6043-3626cd5b7e42e0ccc76d142e8ec88de883c8267636fe2ef194a7ca6c9ff8138d3 |
| IEDL.DBID | RPM |
| ISSN | 2574-173X |
| IngestDate | Thu Sep 05 15:32:46 EDT 2024 Tue Sep 17 21:21:35 EDT 2024 Fri Aug 16 05:27:35 EDT 2024 Tue Sep 24 23:19:31 EDT 2024 Tue Sep 17 07:49:37 EDT 2024 Thu May 23 23:46:03 EDT 2024 Sat Aug 24 01:00:19 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Attribution This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6043-3626cd5b7e42e0ccc76d142e8ec88de883c8267636fe2ef194a7ca6c9ff8138d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411321/ |
| PMID | 34390232 |
| PQID | 2568152435 |
| PQPubID | 4378887 |
| PageCount | 0 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d74f4564139748bc84bed7caab95fbe9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8411321 proquest_miscellaneous_2561490600 proquest_journals_2568152435 crossref_primary_10_1002_npr2_12193 pubmed_primary_34390232 wiley_primary_10_1002_npr2_12193_NPR212193 |
| PublicationCentury | 2000 |
| PublicationDate | September 2021 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: September 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Neuropsychopharmacology reports |
| PublicationTitleAlternate | Neuropsychopharmacol Rep |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | e_1_2_17_2_6_1 Motohashi N (e_1_2_35_2_5_1) 2013; 115 e_1_2_42_2_40_1 e_1_2_36_2_22_1 Siris SG (e_1_2_39_2_17_1) 1990; 26 e_1_2_42_2_86_1 e_1_2_31_14_4_1 e_1_2_34_2_19_1 e_1_2_40_2_14_1 e_1_2_44_2_25_1 e_1_2_21_4_19_1 e_1_2_33_2_15_1 e_1_2_37_9_28_1 e_1_2_41_2_29_1 e_1_2_42_2_3_1 e_1_2_32_2_11_1 Soares‐Weiser K (e_1_2_42_2_70_1) 2006; 1 e_1_2_18_2_13_1 e_1_2_36_2_5_1 e_1_2_41_2_9_1 e_1_2_36_2_10_1 e_1_2_42_2_51_1 Hatta S (e_1_2_37_9_18_1) e_1_2_38_2_8_1 e_1_2_28_2_3_1 e_1_2_38_2_18_1 e_1_2_43_2_10_1 e_1_2_33_2_9_1 e_1_2_34_2_2_1 e_1_2_42_2_74_1 e_1_2_23_2_4_1 e_1_2_40_2_26_1 e_1_2_44_2_36_1 e_1_2_33_2_26_1 e_1_2_37_9_39_1 Yamaji K (e_1_2_31_14_9_1) 2012; 15 Taylor D (e_1_2_31_14_5_1) 2012 e_1_2_44_2_5_1 e_1_2_22_2_28_1 e_1_2_32_2_23_1 e_1_2_37_9_16_1 Rosebush PI (e_1_2_38_2_10_1) 1990; 51 Kajiyama H (e_1_2_41_2_16_1) 2002; 5 e_1_2_18_2_25_1 e_1_2_36_2_21_1 Goldstein JA (e_1_2_41_2_32_1) 1986; 47 e_1_2_44_2_24_1 e_1_2_42_2_41_1 e_1_2_42_2_87_1 e_1_2_43_2_20_1 e_1_2_42_2_64_1 e_1_2_17_2_7_1 e_1_2_40_2_15_1 e_1_2_34_2_18_1 Tharyan P (e_1_2_35_2_2_1) 2005; 2 e_1_2_37_9_29_1 e_1_2_33_2_16_1 Silver H (e_1_2_42_2_38_1) 1995; 56 Powney MJ (e_1_2_37_9_30_1) 2012; 11 e_1_2_42_2_4_1 e_1_2_32_2_12_1 e_1_2_18_2_12_1 e_1_2_22_2_15_1 e_1_2_17_2_10_1 Essali A (e_1_2_32_2_8_1) 2009 e_1_2_36_2_4_1 e_1_2_41_2_8_1 e_1_2_38_2_9_1 e_1_2_44_2_12_1 e_1_2_44_2_35_1 e_1_2_34_2_3_1 e_1_2_42_2_52_1 e_1_2_42_2_75_1 e_1_2_40_2_27_1 Kawakami H (e_1_2_41_2_13_1) 2010; 13 e_1_2_28_2_2_1 e_1_2_38_2_19_1 e_1_2_32_2_24_1 e_1_2_37_9_17_1 e_1_2_23_2_3_1 e_1_2_33_2_27_1 e_1_2_22_2_27_1 e_1_2_39_2_2_1 Misawa H (e_1_2_41_2_17_1) 2002; 44 e_1_2_44_2_6_1 e_1_2_19_2_8_1 e_1_2_18_2_24_1 e_1_2_17_2_4_1 Munn NA (e_1_2_41_2_7_1) 1993; 54 e_1_2_40_2_2_1 e_1_2_36_2_20_1 Leon J (e_1_2_41_2_2_1) 2003; 253 e_1_2_42_2_42_1 e_1_2_42_2_65_1 e_1_2_42_2_88_1 e_1_2_40_2_16_1 e_1_2_44_2_27_1 e_1_2_34_2_17_1 e_1_2_33_2_36_1 Kinoshita T (e_1_2_22_2_18_1) 2014; 175 e_1_2_33_2_13_1 Inenaga K (e_1_2_41_2_21_1) 2007; 25 e_1_2_18_2_11_1 Syed R (e_1_2_33_2_4_1) 2008; 3 e_1_2_22_2_14_1 e_1_2_35_2_9_1 e_1_2_29_2_10_1 Lawson WB (e_1_2_41_2_33_1) 1988; 24 e_1_2_36_2_3_1 Kinon BJ (e_1_2_37_9_12_1) 2001; 62 e_1_2_44_2_3_1 e_1_2_42_2_30_1 e_1_2_42_2_76_1 e_1_2_42_2_53_1 e_1_2_33_2_7_1 e_1_2_40_2_28_1 e_1_2_44_2_15_1 e_1_2_23_2_6_1 e_1_2_39_2_3_1 e_1_2_22_2_26_1 e_1_2_32_2_21_1 e_1_2_33_2_24_1 e_1_2_19_2_7_1 e_1_2_18_2_23_1 e_1_2_17_2_5_1 e_1_2_42_2_20_1 e_1_2_42_2_43_1 e_1_2_42_2_66_1 e_1_2_40_2_17_1 e_1_2_44_2_26_1 e_1_2_33_2_14_1 e_1_2_42_2_2_1 e_1_2_33_2_37_1 e_1_2_34_2_16_1 Leucht S (e_1_2_39_2_20_1) 2007; 3 e_1_2_18_2_10_1 Watanabe K (e_1_2_41_2_27_1) 2005; 8 e_1_2_22_2_13_1 e_1_2_29_2_11_1 Yamawaki S (e_1_2_43_2_12_1) 1993; 27 e_1_2_36_2_2_1 e_1_2_42_2_31_1 e_1_2_42_2_54_1 e_1_2_42_2_77_1 e_1_2_44_2_4_1 e_1_2_40_2_29_1 e_1_2_43_2_11_1 e_1_2_23_2_5_1 e_1_2_33_2_8_1 e_1_2_44_2_37_1 e_1_2_44_2_14_1 e_1_2_33_2_25_1 e_1_2_39_2_4_1 e_1_2_37_9_19_1 Lehman AF (e_1_2_18_2_2_1) 2004; 161 e_1_2_22_2_25_1 e_1_2_32_2_22_1 e_1_2_18_2_22_1 e_1_2_29_2_9_1 e_1_2_19_2_6_1 Hashimoto R (e_1_2_31_14_8_1) 2012; 15 e_1_2_22_2_7_1 e_1_2_20_2_4_1 e_1_2_42_2_82_1 e_1_2_39_2_22_1 Takada H (e_1_2_41_2_11_1) 1998; 40 e_1_2_44_2_21_1 e_1_2_18_2_17_1 e_1_2_34_2_15_1 e_1_2_40_2_10_1 e_1_2_40_2_33_1 e_1_2_42_2_29_1 e_1_2_33_2_11_1 e_1_2_33_2_34_1 e_1_2_32_2_30_1 e_1_2_17_2_13_1 e_1_2_22_2_12_1 e_1_2_37_9_3_1 e_1_2_39_2_11_1 e_1_2_23_2_8_1 e_1_2_44_2_32_1 e_1_2_41_2_37_1 e_1_2_18_2_29_1 e_1_2_22_2_24_1 e_1_2_40_2_22_1 e_1_2_33_2_22_1 e_1_2_44_2_20_1 e_1_2_20_2_5_1 e_1_2_42_2_83_1 e_1_2_22_2_6_1 e_1_2_39_2_21_1 Fujiwara T (e_1_2_33_2_40_1) 2010; 28 Stübner S (e_1_2_43_2_2_1) 2004; 37 Murasaki M (e_1_2_42_2_17_1) 1999; 19 e_1_2_40_2_34_1 e_1_2_40_2_11_1 Suttajit S (e_1_2_42_2_45_1) 2013; 5 e_1_2_33_2_35_1 e_1_2_34_2_14_1 e_1_2_33_2_12_1 e_1_2_18_2_16_1 e_1_2_22_2_11_1 e_1_2_17_2_14_1 e_1_2_37_9_4_1 Taylor D (e_1_2_33_2_38_1) 2012 Huf G (e_1_2_37_9_26_1) 2009; 3 e_1_2_44_2_31_1 Barbee JG (e_1_2_24_2_2_1) 1992; 149 e_1_2_39_2_10_1 e_1_2_42_2_71_1 McGorry PD (e_1_2_18_2_28_1) 2011; 631690 Motohashi N (e_1_2_31_14_7_1) 2013; 115 e_1_2_23_2_7_1 e_1_2_41_2_26_1 e_1_2_40_2_23_1 e_1_2_24_2_8_1 e_1_2_41_2_38_1 e_1_2_22_2_23_1 e_1_2_42_2_18_1 e_1_2_32_2_20_1 e_1_2_33_2_23_1 Lehman AF (e_1_2_39_2_6_1) 2004; 161 e_1_2_38_2_20_1 Borison RL (e_1_2_22_2_16_1) 1991; 27 e_1_2_42_2_84_1 e_1_2_25_7_2_1 e_1_2_31_14_2_1 e_1_2_44_2_23_1 e_1_2_17_2_8_1 Gibson RC (e_1_2_38_2_5_1) 2008; 4 e_1_2_40_2_12_1 e_1_2_40_2_35_1 e_1_2_34_2_13_1 e_1_2_33_2_32_1 e_1_2_17_2_11_1 e_1_2_18_2_15_1 e_1_2_22_2_10_1 e_1_2_39_2_13_1 e_1_2_42_2_72_1 e_1_2_21_4_20_1 Donnelly L (e_1_2_42_2_33_1) 2013; 8 e_1_2_44_2_34_1 e_1_2_16_3_5_1 e_1_2_44_2_11_1 e_1_2_22_2_22_1 e_1_2_40_2_24_1 e_1_2_42_2_19_1 e_1_2_33_2_20_1 e_1_2_18_2_27_1 Cutler AJ (e_1_2_22_2_8_1) 2010; 43 e_1_2_42_2_62_1 Lehman AF (e_1_2_21_4_3_1) 2004; 161 e_1_2_21_4_10_1 e_1_2_44_2_22_1 e_1_2_42_2_85_1 e_1_2_17_2_9_1 e_1_2_40_2_13_1 (e_1_2_33_2_41_1) 2013 e_1_2_33_2_10_1 e_1_2_33_2_33_1 e_1_2_34_2_12_1 Escobar R (e_1_2_37_9_7_1) 2008; 36 e_1_2_17_2_12_1 e_1_2_21_4_4_1 e_1_2_18_2_14_1 e_1_2_18_2_9_1 e_1_2_39_2_12_1 e_1_2_37_9_2_1 Matsuda G (e_1_2_41_2_3_1) 1989; 18 e_1_2_42_2_50_1 e_1_2_42_2_73_1 e_1_2_21_4_21_1 e_1_2_23_2_9_1 e_1_2_44_2_10_1 e_1_2_44_2_33_1 Brookes G (e_1_2_41_2_43_1) 2006; 4 e_1_2_36_2_19_1 e_1_2_40_2_25_1 e_1_2_22_2_21_1 e_1_2_33_2_21_1 Yamamura S (e_1_2_41_2_20_1) 2003; 21 e_1_2_18_2_26_1 e_1_2_30_2_4_1 e_1_2_40_2_8_1 e_1_2_27_2_2_1 e_1_2_21_4_11_1 e_1_2_37_9_31_1 e_1_2_32_2_7_1 Lehman AF (e_1_2_19_2_3_1) 2004; 161 e_1_2_42_2_48_1 e_1_2_32_2_19_1 e_1_2_42_2_25_1 e_1_2_23_2_12_1 e_1_2_34_2_11_1 Enomoto T (e_1_2_41_2_12_1) 2005; 8 e_1_2_33_2_30_1 Ichie R (e_1_2_41_2_31_1) 2004; 7 e_1_2_22_2_3_1 e_1_2_35_2_3_1 e_1_2_21_4_5_1 e_1_2_18_2_8_1 e_1_2_39_2_15_1 Irwin M (e_1_2_42_2_60_1) 1988; 10 e_1_2_21_4_22_1 e_1_2_16_3_3_1 e_1_2_36_2_18_1 e_1_2_42_2_13_1 e_1_2_42_2_59_1 e_1_2_42_2_36_1 e_1_2_43_2_18_1 e_1_2_29_2_4_1 Fukuda M (e_1_2_41_2_18_1) 2002; 5 e_1_2_24_2_5_1 Nakamura J (e_1_2_41_2_25_1) 1998; 1 CADTH (e_1_2_21_4_30_1) 2011 e_1_2_39_2_9_1 e_1_2_22_2_20_1 e_1_2_30_2_5_1 e_1_2_40_2_7_1 e_1_2_25_7_3_1 e_1_2_32_2_6_1 e_1_2_21_4_12_1 e_1_2_37_9_32_1 American Psychiatric Association (e_1_2_31_14_3_1) 2004 e_1_2_42_2_26_1 e_1_2_43_2_5_1 e_1_2_23_2_11_1 e_1_2_42_2_49_1 e_1_2_40_2_30_1 e_1_2_33_2_31_1 e_1_2_22_2_2_1 e_1_2_22_2_30_1 e_1_2_21_4_6_1 e_1_2_18_2_7_1 e_1_2_39_2_14_1 e_1_2_37_9_8_1 e_1_2_42_2_90_1 e_1_2_38_2_11_1 e_1_2_16_3_4_1 e_1_2_37_9_20_1 e_1_2_21_4_23_1 e_1_2_36_2_17_1 e_1_2_41_2_34_1 e_1_2_42_2_14_1 e_1_2_42_2_37_1 e_1_2_33_2_2_1 e_1_2_24_2_4_1 Liu X (e_1_2_42_2_34_1) 2009; 2 e_1_2_29_2_3_1 Ichikawa R (e_1_2_41_2_14_1) 2010; 13 e_1_2_33_2_42_1 Inada T (e_1_2_42_2_89_1) 1991; 45 e_1_2_42_2_80_1 e_1_2_30_2_6_1 Inada T (e_1_2_41_2_23_1) 2003; 6 e_1_2_22_2_5_1 e_1_2_21_4_13_1 e_1_2_37_9_33_1 e_1_2_42_2_9_1 e_1_2_32_2_17_1 Yamashita T (e_1_2_41_2_24_1) 2010; 17 e_1_2_37_9_10_1 Kobayashi K (e_1_2_41_2_19_1) 2007; 19 e_1_2_18_2_19_1 e_1_2_42_2_27_1 Macfadden W (e_1_2_28_2_5_1) 2010; 7 e_1_2_40_2_31_1 Arai I (e_1_2_41_2_22_1) 2009; 14 McQuade RD (e_1_2_22_2_29_1) 2004; 65 Sanga M (e_1_2_41_2_39_1) 1999; 19 e_1_2_17_2_15_1 e_1_2_21_4_7_1 Agid O (e_1_2_21_4_8_1) 2006; 31 e_1_2_23_2_10_1 Wirshing DA (e_1_2_44_2_2_1) 2004; 65 e_1_2_37_9_5_1 e_1_2_18_2_6_1 Lindenmayer JP (e_1_2_22_2_9_1) 2008; 41 e_1_2_26_2_6_1 e_1_2_44_2_30_1 e_1_2_38_2_12_1 e_1_2_37_9_21_1 e_1_2_21_4_24_1 e_1_2_36_2_16_1 e_1_2_38_2_2_1 e_1_2_32_2_29_1 e_1_2_41_2_35_1 e_1_2_42_2_15_1 e_1_2_34_2_8_1 e_1_2_40_2_20_1 e_1_2_29_2_2_1 e_1_2_34_2_21_1 Powney MJ (e_1_2_42_2_44_1) 2012; 11 e_1_2_20_2_3_1 e_1_2_42_2_81_1 e_1_2_25_7_5_1 e_1_2_21_4_14_1 e_1_2_32_2_18_1 e_1_2_37_9_11_1 e_1_2_43_2_3_1 e_1_2_42_2_28_1 e_1_2_18_2_18_1 e_1_2_40_2_32_1 Iwazaki S (e_1_2_41_2_28_1) 2009; 58 e_1_2_22_2_4_1 Goswami U (e_1_2_35_2_7_1) 2003; 45 Sakkas P (e_1_2_43_2_9_1) 1991; 27 e_1_2_40_2_9_1 Iwanaga H (e_1_2_41_2_15_1) 2010; 13 Lehman AF (e_1_2_16_3_2_1) 2004; 161 Asenjo Lobos C (e_1_2_32_2_10_1) 2010; 11 e_1_2_28_2_8_1 e_1_2_38_2_13_1 e_1_2_26_2_7_1 e_1_2_37_9_6_1 e_1_2_36_2_15_1 e_1_2_37_9_22_1 e_1_2_21_4_25_1 e_1_2_18_2_5_1 e_1_2_39_2_16_1 e_1_2_38_2_3_1 Buchanan RW (e_1_2_32_2_2_1) 1998; 155 e_1_2_34_2_9_1 e_1_2_42_2_16_1 e_1_2_42_2_39_1 e_1_2_40_2_21_1 e_1_2_43_2_19_1 e_1_2_24_2_6_1 e_1_2_34_2_20_1 Goldstein MB (e_1_2_41_2_36_1) 1991; 74 e_1_2_17_2_2_1 e_1_2_40_2_4_1 e_1_2_42_2_7_1 e_1_2_40_2_18_1 e_1_2_21_4_15_1 e_1_2_33_2_19_1 e_1_2_42_2_67_1 e_1_2_32_2_15_1 e_1_2_43_2_8_1 e_1_2_44_2_29_1 e_1_2_37_9_24_1 e_1_2_32_2_3_1 e_1_2_21_4_9_1 e_1_2_35_2_11_1 Gillies D (e_1_2_37_9_35_1) 2013; 4 Kinon BJ (e_1_2_21_4_2_1) 1993; 29 Kakimoto Y (e_1_2_41_2_40_1) 2010; 52 e_1_2_26_2_4_1 e_1_2_28_2_7_1 e_1_2_38_2_14_1 e_1_2_36_2_14_1 e_1_2_42_2_55_1 e_1_2_38_2_4_1 e_1_2_37_9_23_1 e_1_2_42_2_32_1 e_1_2_21_4_26_1 e_1_2_43_2_14_1 e_1_2_44_2_17_1 e_1_2_18_2_4_1 e_1_2_33_2_5_1 e_1_2_39_2_19_1 e_1_2_42_2_78_1 Leucht S (e_1_2_24_2_7_1) 2014; 5 Behdani F (e_1_2_34_2_10_1) 2011; 14 e_1_2_39_2_5_1 e_1_2_44_2_9_1 e_1_2_32_2_27_1 Wirshing DA (e_1_2_36_2_9_1) 1999; 156 e_1_2_34_2_6_1 e_1_2_29_2_8_1 e_1_2_19_2_5_1 e_1_2_18_2_21_1 e_1_2_41_2_5_1 e_1_2_17_2_3_1 e_1_2_22_2_19_1 e_1_2_40_2_3_1 e_1_2_42_2_8_1 e_1_2_41_2_41_1 e_1_2_42_2_22_1 e_1_2_40_2_19_1 e_1_2_44_2_28_1 e_1_2_21_4_16_1 e_1_2_42_2_68_1 Lehman AF (e_1_2_42_2_46_1) 2004; 161 e_1_2_32_2_16_1 e_1_2_37_9_25_1 e_1_2_35_2_10_1 e_1_2_35_2_8_1 e_1_2_26_2_5_1 e_1_2_36_2_8_1 e_1_2_36_2_13_1 Lieberman JA (e_1_2_25_7_4_1) 1996; 57 e_1_2_41_2_30_1 e_1_2_42_2_10_1 e_1_2_28_2_6_1 e_1_2_38_2_15_1 e_1_2_32_2_28_1 e_1_2_21_4_27_1 e_1_2_43_2_13_1 e_1_2_44_2_16_1 e_1_2_18_2_3_1 e_1_2_39_2_18_1 e_1_2_42_2_56_1 e_1_2_42_2_79_1 e_1_2_33_2_6_1 Lima AR (e_1_2_42_2_61_1) 2004; 4 e_1_2_37_9_13_1 e_1_2_37_9_36_1 e_1_2_19_2_4_1 e_1_2_34_2_7_1 e_1_2_18_2_20_1 e_1_2_29_2_7_1 Ishimoto K (e_1_2_37_9_34_1) 2012 Davis JM (e_1_2_43_2_17_1) 1991; 7 e_1_2_41_2_4_1 e_1_2_40_2_6_1 e_1_2_27_2_4_1 Horiguchi J (e_1_2_42_2_63_1) 1992; 46 e_1_2_36_2_24_1 e_1_2_41_2_42_1 e_1_2_42_2_23_1 e_1_2_42_2_69_1 e_1_2_21_4_17_1 e_1_2_32_2_13_1 e_1_2_43_2_6_1 e_1_2_33_2_17_1 e_1_2_32_2_5_1 e_1_2_42_2_5_1 e_1_2_26_2_2_1 e_1_2_36_2_7_1 e_1_2_37_9_9_1 e_1_2_36_2_12_1 e_1_2_38_2_6_1 e_1_2_38_2_16_1 e_1_2_42_2_11_1 Caroff SN (e_1_2_43_2_4_1) 2003 Arman S (e_1_2_44_2_13_1) 2008; 29 e_1_2_21_4_28_1 e_1_2_43_2_16_1 e_1_2_42_2_57_1 e_1_2_33_2_3_1 e_1_2_32_2_25_1 e_1_2_33_2_28_1 e_1_2_44_2_19_1 e_1_2_23_2_2_1 e_1_2_24_2_3_1 e_1_2_44_2_7_1 e_1_2_34_2_4_1 e_1_2_37_9_14_1 e_1_2_37_9_37_1 Fujii Y (e_1_2_33_2 |
| References_xml | – ident: e_1_2_37_9_15_1 doi: 10.1097/00131746-200603000-00005 – ident: e_1_2_42_2_11_1 doi: 10.1046/j.1440-1819.2001.00882.x – ident: e_1_2_33_2_26_1 doi: 10.1097/01.pra.0000369974.18274.e2 – ident: e_1_2_26_2_3_1 doi: 10.1001/jamapsychiatry.2013.149 – ident: e_1_2_29_2_8_1 doi: 10.1016/j.euroneuro.2008.04.012 – volume: 19 start-page: 31 year: 2007 ident: e_1_2_41_2_19_1 article-title: Effects of quetiapine against water intoxication publication-title: Clinical Medicine in Tomorrow contributor: fullname: Kobayashi K – ident: e_1_2_17_2_9_1 doi: 10.1176/appi.ajp.163.12.2096 – volume: 3 start-page: CD005579 year: 2008 ident: e_1_2_33_2_4_1 article-title: Pharmacological interventions for clozapine‐induced hypersalivation publication-title: Cochrane Database Syst Rev contributor: fullname: Syed R – ident: e_1_2_17_2_3_1 doi: 10.1017/S1461145712001277 – ident: e_1_2_35_2_6_1 doi: 10.1176/appi.ps.52.8.1095 – ident: e_1_2_22_2_12_1 doi: 10.4088/JCP.12m07642 – ident: e_1_2_22_2_28_1 doi: 10.4088/JCP.v68n0104 – ident: e_1_2_22_2_21_1 doi: 10.1016/S0893-133X(98)00090-6 – ident: e_1_2_36_2_3_1 doi: 10.1097/jcp.0b013e31815abf34 – volume: 52 start-page: 1103 year: 2010 ident: e_1_2_41_2_40_1 article-title: Treatment of polydipsia and water intoxication of schizophrenic patients by carbamazepine publication-title: Seishin Igaku contributor: fullname: Kakimoto Y – ident: e_1_2_42_2_40_1 doi: 10.1097/00004714-199904000-00009 – ident: e_1_2_22_2_17_1 doi: 10.1034/j.1600-0447.2000.101003218.x – ident: e_1_2_44_2_5_1 doi: 10.1017/S0033291798008186 – volume: 10 start-page: 244 year: 1988 ident: e_1_2_42_2_60_1 article-title: Propranolol as a primary treatment of neuroleptic‐induced akathisia publication-title: Hillside J Clin Psychiatry contributor: fullname: Irwin M – ident: e_1_2_24_2_8_1 doi: 10.1111/j.1440-1819.2004.01269.x – ident: e_1_2_35_2_11_1 doi: 10.1097/00124509-200206000-00005 – ident: e_1_2_37_9_25_1 doi: 10.1016/j.eurpsy.2004.07.001 – ident: e_1_2_22_2_13_1 doi: 10.2165/00023210-200923070-00006 – ident: e_1_2_32_2_21_1 doi: 10.1176/ajp.155.4.499 – ident: e_1_2_36_2_11_1 doi: 10.1176/ajp.155.7.914 – ident: e_1_2_44_2_20_1 doi: 10.1016/j.schres.2012.02.021 – ident: e_1_2_26_2_2_1 doi: 10.1016/S0140-6736(12)60239-6 – ident: e_1_2_42_2_65_1 doi: 10.1097/01.jcp.0000084027.22282.16 – ident: e_1_2_33_2_29_1 doi: 10.4088/JCP.v69n0509 – ident: e_1_2_42_2_50_1 doi: 10.1176/appi.ajp.2008.08050756 – ident: e_1_2_34_2_18_1 doi: 10.1097/01.pra.0000336753.11943.7c – ident: e_1_2_41_2_29_1 doi: 10.1038/npp.1993.54 – ident: e_1_2_34_2_21_1 – ident: e_1_2_40_2_17_1 doi: 10.1017/S146114570500516X – ident: e_1_2_32_2_7_1 doi: 10.1097/00004850-199705000-00001 – volume: 3 start-page: CD003834 year: 2007 ident: e_1_2_39_2_20_1 article-title: Lithium for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Leucht S – ident: e_1_2_40_2_7_1 doi: 10.1007/s00213-003-1506-y – ident: e_1_2_39_2_21_1 doi: 10.1111/j.1600-0447.1995.tb09572.x – ident: e_1_2_16_3_5_1 doi: 10.3109/15622975.2012.696143 – ident: e_1_2_43_2_10_1 doi: 10.3928/0048-5713-20000501-10 – ident: e_1_2_44_2_18_1 doi: 10.1176/appi.ajp.2013.12010127 – ident: e_1_2_39_2_15_1 doi: 10.1002/gps.508 – ident: e_1_2_42_2_19_1 doi: 10.1017/S1461145703003651 – volume: 58 start-page: 2006 year: 2009 ident: e_1_2_41_2_28_1 article-title: A case where risperidone oral solution (RIS‐OS) was effective against persistent psychomotor agitation in a severe chronic schizophrenia patient with polydipsia in long‐term isolation — Including the usefulness of RIS‐OS maintenance therapy publication-title: J New Rem & Clin contributor: fullname: Iwazaki S – ident: e_1_2_39_2_3_1 doi: 10.1093/schbul/sbn135 – ident: e_1_2_42_2_6_1 doi: 10.1001/archpsyc.1988.01800330013001 – ident: e_1_2_26_2_5_1 doi: 10.1097/01.jcp.0000195109.01898.5e – ident: e_1_2_32_2_28_1 doi: 10.4088/JCP.v68n0601 – ident: e_1_2_40_2_8_1 doi: 10.1177/0269881111405555 – ident: e_1_2_34_2_12_1 doi: 10.1097/00004714-200306000-00002 – ident: e_1_2_37_9_33_1 doi: 10.1176/appi.ajp.158.7.1149 – ident: e_1_2_44_2_9_1 doi: 10.4088/JCP.v69n0702 – volume: 24 start-page: 176 year: 1988 ident: e_1_2_41_2_33_1 article-title: Effects of captopril on psychosis and disturbed water regulation publication-title: Psychopharmacol Bull contributor: fullname: Lawson WB – ident: e_1_2_37_9_32_1 doi: 10.1016/j.eurpsy.2006.03.005 – ident: e_1_2_18_2_14_1 doi: 10.1176/appi.ajp.163.12.2096 – ident: e_1_2_18_2_19_1 doi: 10.1176/ajp.2007.164.7.1050 – volume: 65 start-page: 47 issue: 18 year: 2004 ident: e_1_2_22_2_29_1 article-title: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study publication-title: J Clin Psychiatry contributor: fullname: McQuade RD – ident: e_1_2_42_2_24_1 doi: 10.1192/bjp.166.6.712 – volume: 45 start-page: 26 year: 2003 ident: e_1_2_35_2_7_1 article-title: Efficacy of electroconvulsive therapy in treatment resistant schizophreinia: a double‐blind study publication-title: Indian J Psychiatry contributor: fullname: Goswami U – ident: e_1_2_23_2_9_1 – ident: e_1_2_23_2_5_1 doi: 10.4088/JCP.v69n0505 – volume: 115 start-page: 580 year: 2013 ident: e_1_2_35_2_5_1 article-title: Recommendations for ECT Practice. Second Edition publication-title: Psychiatria et Neurologia Japonica contributor: fullname: Motohashi N – ident: e_1_2_44_2_19_1 doi: 10.1176/ajp.2006.163.12.2072 – volume: 5 start-page: CD008016 year: 2012 ident: e_1_2_20_2_2_1 article-title: Maintenance treatment with antipsychotic drugs for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Leucht S – ident: e_1_2_37_9_36_1 doi: 10.1016/j.psychres.2009.03.030 – ident: e_1_2_44_2_31_1 doi: 10.1016/j.euroneuro.2004.03.005 – ident: e_1_2_34_2_6_1 doi: 10.1016/j.schres.2007.02.009 – ident: e_1_2_42_2_53_1 doi: 10.1097/YCO.0b013e32832a16da – ident: e_1_2_44_2_30_1 doi: 10.1016/S0924-977X(02)00127-X – ident: e_1_2_38_2_3_1 doi: 10.1176/jnp.23.2.jnp223 – ident: e_1_2_21_4_13_1 doi: 10.1093/schbul/sbm134 – ident: e_1_2_23_2_3_1 doi: 10.1016/j.schres.2014.07.015 – volume: 17 start-page: 1595 year: 2014 ident: e_1_2_31_14_10_1 article-title: Treatment strategies and pathology research for treatment‐resistant schizophrenia — true treatment‐resistant schizophrenia and apparent treatment‐resistant schizophrenia publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Hashimoto R – ident: e_1_2_37_9_39_1 doi: 10.1016/j.schres.2013.02.005 – ident: e_1_2_42_2_86_1 doi: 10.4088/JCP.v64n1110 – ident: e_1_2_38_2_4_1 doi: 10.1097/JCP.0b013e3181c9bfe6 – ident: e_1_2_42_2_15_1 doi: 10.1016/S0006-3223(97)00190-X – ident: e_1_2_19_2_6_1 doi: 10.1192/bjp.bp.109.069328 – ident: e_1_2_36_2_22_1 doi: 10.1016/S0140-6736(09)60742-X – ident: e_1_2_32_2_11_1 doi: 10.1016/j.biopsych.2007.04.043 – ident: e_1_2_39_2_10_1 doi: 10.1186/1471-244X-11-145 – ident: e_1_2_42_2_82_1 doi: 10.1176/ajp.145.8.993 – ident: e_1_2_35_2_8_1 doi: 10.1097/00124509-199906000-00004 – ident: e_1_2_31_14_4_1 – ident: e_1_2_33_2_23_1 doi: 10.1177/0269881105048902 – volume: 115 start-page: 580 year: 2013 ident: e_1_2_31_14_7_1 article-title: Recommendations for ECT Practice publication-title: Second Edition. Psychiatria et Neurologia Japonica contributor: fullname: Motohashi N – ident: e_1_2_43_2_19_1 doi: 10.1111/j.1440-1819.2009.02042.x – ident: e_1_2_17_2_15_1 – ident: e_1_2_32_2_15_1 doi: 10.1111/j.1600-0447.2004.00450.x – ident: e_1_2_22_2_25_1 doi: 10.1097/00004714-199602000-00007 – ident: e_1_2_37_9_27_1 doi: 10.1136/bmj.39339.448819.AE – volume: 28 start-page: 48 year: 2010 ident: e_1_2_33_2_40_1 article-title: Guidelines for pharmacological therapy of epilepsy using new antiepileptic drugs publication-title: J Jpn Epil Soc contributor: fullname: Fujiwara T – ident: e_1_2_22_2_10_1 doi: 10.1016/0893-133X(95)00069-P – ident: e_1_2_37_9_3_1 doi: 10.1093/schbul/sbp116 – ident: e_1_2_18_2_26_1 doi: 10.1176/appi.ajp.162.5.947 – ident: e_1_2_22_2_20_1 doi: 10.1007/s00213-012-2838-2 – volume: 5 start-page: CD007815 year: 2013 ident: e_1_2_42_2_45_1 article-title: Quetiapine versus typical antipsychotic medications for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Suttajit S – start-page: CD000059 year: 2009 ident: e_1_2_32_2_8_1 article-title: Clozapine versus typical neuroleptic medication for schizophrenia publication-title: Cochrane Database Syst Rev (1) contributor: fullname: Essali A – ident: e_1_2_17_2_8_1 doi: 10.3109/15622970802309617 – ident: e_1_2_18_2_17_1 doi: 10.4088/JCP.09m05785yel – ident: e_1_2_42_2_57_1 doi: 10.1192/bjp.166.2.241 – ident: e_1_2_18_2_13_1 doi: 10.4088/JCP.v67n1004 – ident: e_1_2_34_2_14_1 doi: 10.1097/YIC.0b013e32834bbc0d – ident: e_1_2_33_2_16_1 doi: 10.1192/bjp.188.3.255 – ident: e_1_2_32_2_4_1 doi: 10.1176/appi.ajp.159.2.255 – volume: 14 start-page: 270 year: 2011 ident: e_1_2_34_2_10_1 article-title: Effect of topiramate augmentation in chronic schizophrenia: a placebo‐controlled trial publication-title: Arch Iran Med contributor: fullname: Behdani F – ident: e_1_2_40_2_14_1 doi: 10.1016/j.pnpbp.2005.10.015 – ident: e_1_2_40_2_18_1 doi: 10.1192/bjp.bp.108.055137 – volume: 27 start-page: 1045 year: 1993 ident: e_1_2_43_2_12_1 article-title: Investigation of the usefulness and administration method of dantrolene sodium against neuroleptic malignant syndrome publication-title: Clinical Report contributor: fullname: Yamawaki S – ident: e_1_2_32_2_30_1 doi: 10.1176/appi.ajp.2011.10081224 – ident: e_1_2_39_2_13_1 doi: 10.1002/hup.1017 – ident: e_1_2_21_4_14_1 doi: 10.1016/j.schres.2008.02.021 – ident: e_1_2_39_2_14_1 doi: 10.1002/hup.1189 – ident: e_1_2_17_2_11_1 doi: 10.1097/00004850-200303000-00008 – ident: e_1_2_32_2_6_1 doi: 10.1001/archpsyc.1988.01800330013001 – volume-title: 100 Q&As for clozapine, clozapine100th Q&A year: 2014 ident: e_1_2_33_2_39_1 contributor: fullname: Fujii Y – ident: e_1_2_34_2_4_1 doi: 10.1007/s00406-004-0517-y – ident: e_1_2_41_2_9_1 doi: 10.1016/0893-133X(94)00069-C – ident: e_1_2_29_2_2_1 doi: 10.1001/archpsyc.1983.01790070083010 – ident: e_1_2_42_2_23_1 doi: 10.1176/ajp.151.6.825 – volume: 57 start-page: 68 issue: 11 year: 1996 ident: e_1_2_25_7_4_1 article-title: Atypical antipsychotic drugs as a first‐line treatment of schizophrenia: a rationale and hypothesis publication-title: J Clin Psychiatry contributor: fullname: Lieberman JA – ident: e_1_2_42_2_73_1 doi: 10.4088/JCP.v65n0516 – ident: e_1_2_18_2_10_1 doi: 10.1002/hup.2270 – volume: 65 start-page: 13 issue: 18 year: 2004 ident: e_1_2_44_2_2_1 article-title: Schizophrenia and obesity: impact of antipsychotic medications publication-title: J Clin Psychiatry contributor: fullname: Wirshing DA – ident: e_1_2_42_2_56_1 doi: 10.1097/jcp.0b013e3180582439 – ident: e_1_2_44_2_11_1 doi: 10.1016/j.schres.2009.05.024 – ident: e_1_2_44_2_32_1 doi: 10.1176/appi.ajp.162.9.1744 – ident: e_1_2_34_2_15_1 doi: 10.1097/00004850-200403000-00003 – ident: e_1_2_29_2_4_1 doi: 10.1001/archpsyc.1988.01800330021002 – ident: e_1_2_18_2_11_1 doi: 10.1007/s00213-013-3241-3 – ident: e_1_2_44_2_26_1 doi: 10.1093/schbul/sbu030 – ident: e_1_2_40_2_6_1 doi: 10.1016/j.schres.2007.08.002 – ident: e_1_2_42_2_55_1 doi: 10.1192/bjp.bp.111.101485 – ident: e_1_2_33_2_25_1 doi: 10.1016/j.schres.2012.08.018 – ident: e_1_2_40_2_25_1 doi: 10.1111/j.1742-1241.2009.02085.x – ident: e_1_2_33_2_24_1 doi: 10.1055/s-2000-8355 – ident: e_1_2_21_4_15_1 doi: 10.1055/s-0029-1234105 – ident: e_1_2_20_2_3_1 doi: 10.1176/appi.ajp.158.11.1835 – ident: e_1_2_42_2_39_1 doi: 10.1016/0010-440X(89)90065-5 – ident: e_1_2_21_4_27_1 doi: 10.1016/j.schres.2012.08.018 – ident: e_1_2_21_4_23_1 doi: 10.1192/bjp.195.52.s63 – ident: e_1_2_17_2_6_1 doi: 10.1002/hup.1257 – volume: 8 start-page: 103 year: 2005 ident: e_1_2_41_2_27_1 article-title: Case of polydipsia in chronic schizophrenia which did not require behavioral constraints for preventing water intoxication due to risperidone oral solution publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Watanabe K – ident: e_1_2_23_2_7_1 doi: 10.1016/j.psc.2012.06.007 – ident: e_1_2_38_2_12_1 doi: 10.1016/j.pnpbp.2010.08.017 – ident: e_1_2_42_2_3_1 doi: 10.2165/11598540-000000000-00000 – ident: e_1_2_36_2_6_1 doi: 10.1097/JCP.0b013e3182970490 – ident: e_1_2_42_2_12_1 doi: 10.1016/S0920-9964(01)00314-0 – volume: 631690 year: 2011 ident: e_1_2_18_2_28_1 article-title: Very low‐dose risperidone in first‐episode psychosis: a safe and effective way to initiate treatment publication-title: Schizophr Res Treatment contributor: fullname: McGorry PD – ident: e_1_2_40_2_15_1 doi: 10.1007/s00213-003-1505-z – ident: e_1_2_41_2_35_1 doi: 10.1016/0278-5846(86)90048-5 – ident: e_1_2_18_2_22_1 doi: 10.1007/s00213-011-2392-3 – volume: 11 start-page: CD009377 year: 2012 ident: e_1_2_37_9_30_1 article-title: Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) publication-title: Cochrane Database Syst Rev contributor: fullname: Powney MJ – ident: e_1_2_18_2_3_1 doi: 10.2165/11314280-000000000-00000 – volume: 37 start-page: S54 issue: 1 year: 2004 ident: e_1_2_43_2_2_1 article-title: Severe and uncommon involuntary movement disorders due to psychotropic drugs publication-title: Pharmcopsychiatry contributor: fullname: Stübner S – ident: e_1_2_32_2_20_1 doi: 10.1016/j.pnpbp.2003.09.033 – volume: 5 start-page: 1053 year: 2002 ident: e_1_2_41_2_18_1 article-title: Polydipsia, water intoxication and new antipsychotic treatment publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Fukuda M – ident: e_1_2_19_2_2_1 doi: 10.1093/schbul/sbp116 – ident: e_1_2_40_2_13_1 doi: 10.1017/S1355617708080090 – ident: e_1_2_22_2_26_1 doi: 10.1007/s00213-004-2082-5 – ident: e_1_2_34_2_17_1 doi: 10.4088/JCP.v65n0607 – ident: e_1_2_44_2_33_1 doi: 10.3371/CSRP.5.1.3 – ident: e_1_2_18_2_6_1 doi: 10.1097/WNF.0b013e31817c6b06 – ident: e_1_2_24_2_3_1 doi: 10.1001/archgenpsychiatry.2011.1532 – ident: e_1_2_32_2_25_1 doi: 10.1111/j.1600-0447.2004.00486.x – ident: e_1_2_42_2_47_1 doi: 10.1097/JCP.0b013e3182677958 – ident: e_1_2_29_2_7_1 doi: 10.1001/archpsyc.1997.01830170079011 – ident: e_1_2_33_2_15_1 doi: 10.1176/ajp.152.4.648 – ident: e_1_2_42_2_85_1 doi: 10.1177/0269881109106306 – ident: e_1_2_33_2_20_1 – ident: e_1_2_42_2_36_1 doi: 10.1177/0269881105057001 – ident: e_1_2_43_2_11_1 doi: 10.3928/0048-5713-19910301-08 – volume: 62 start-page: 17 issue: 2 year: 2001 ident: e_1_2_37_9_12_1 article-title: Effective resolusion with olanzapine of acute presentation of behavioral agitation and positive psychiatric symptoms in schizophrenia publication-title: J Clin Psychiatry contributor: fullname: Kinon BJ – ident: e_1_2_22_2_11_1 doi: 10.1097/JCP.0b013e318218dcd5 – ident: e_1_2_21_4_24_1 doi: 10.1080/13651500802085369 – ident: e_1_2_40_2_12_1 doi: 10.1055/s-2007-979481 – ident: e_1_2_42_2_76_1 doi: 10.4088/JCP.09m05125yel – ident: e_1_2_43_2_7_1 doi: 10.1016/S0006-3223(98)00109-7 – volume: 7 start-page: 111 year: 1991 ident: e_1_2_43_2_17_1 article-title: Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome publication-title: Convuls Ther contributor: fullname: Davis JM – volume: 1 start-page: CD000459 year: 2006 ident: e_1_2_42_2_70_1 article-title: Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia publication-title: Cochrane Database Syst Rev contributor: fullname: Soares‐Weiser K – ident: e_1_2_42_2_71_1 doi: 10.1007/s004060050039 – ident: e_1_2_33_2_6_1 doi: 10.1136/jcp.53.6.481 – ident: e_1_2_38_2_15_1 doi: 10.1080/10401230802017092 – ident: e_1_2_42_2_80_1 doi: 10.4088/JCP.08m04315 – ident: e_1_2_17_2_2_1 doi: 10.1016/S0140-6736(12)60239-6 – ident: e_1_2_32_2_22_1 doi: 10.1097/01.jcp.0000096246.29231.73 – volume: 156 start-page: 1374 year: 1999 ident: e_1_2_36_2_9_1 article-title: Risperidone in treatment‐refractory schizophrenia publication-title: Am J Psychiatry doi: 10.1176/ajp.156.9.1374 contributor: fullname: Wirshing DA – ident: e_1_2_18_2_23_1 doi: 10.1056/NEJMoa051688 – ident: e_1_2_33_2_5_1 doi: 10.1007/s002130051008 – ident: e_1_2_42_2_54_1 doi: 10.1192/bjp.bp.108.050088 – ident: e_1_2_22_2_15_1 doi: 10.1001/archpsyc.1971.01750170020004 – volume: 13 start-page: 646 year: 2010 ident: e_1_2_41_2_15_1 article-title: A case of chronic dismantling schizophrenia where behavioral restrictions associated with water intoxication were eliminated by clozapine administration publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Iwanaga H – ident: e_1_2_42_2_8_1 doi: 10.1016/S0924-977X(96)00392-6 – ident: e_1_2_21_4_17_1 doi: 10.1038/npp.2009.164 – volume: 4 start-page: CD006570 year: 2008 ident: e_1_2_38_2_5_1 article-title: Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses publication-title: Cochrane Database Syst Rev contributor: fullname: Gibson RC – ident: e_1_2_33_2_32_1 doi: 10.4088/JCP.09m05274yel – ident: e_1_2_42_2_20_1 doi: 10.4088/JCP.v68n0206 – ident: e_1_2_42_2_43_1 doi: 10.1177/0269881108096070 – volume: 2 start-page: CD000076 year: 2005 ident: e_1_2_35_2_2_1 article-title: Electroconvulsive therapy for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Tharyan P – ident: e_1_2_42_2_77_1 doi: 10.4088/JCP.v68n0709 – ident: e_1_2_16_3_4_1 doi: 10.1093/schbul/sbp116 – ident: e_1_2_29_2_10_1 doi: 10.1093/schbul/sbt090 – ident: e_1_2_33_2_22_1 doi: 10.1177/070674370705200708 – volume: 8 start-page: 2080 year: 2005 ident: e_1_2_41_2_12_1 article-title: A case where clozapine was effective against water intoxication publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Enomoto T – volume: 56 start-page: 167 year: 1995 ident: e_1_2_42_2_38_1 article-title: No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients publication-title: J Clin Psychiatry contributor: fullname: Silver H – volume: 253 start-page: 37 year: 2003 ident: e_1_2_41_2_2_1 article-title: Polydipsia‐a study in a long‐term psychiatric unit publication-title: Eur Arch Psychiatry Clin Neurosci contributor: fullname: Leon J – ident: e_1_2_43_2_3_1 doi: 10.1192/bjp.161.2.254 – volume: 25 start-page: 25 year: 2007 ident: e_1_2_41_2_21_1 article-title: Aripiprazole therapy of polydipsia publication-title: Bulletin of Chikusuikai Institute for Neuroinformation and Hospital contributor: fullname: Inenaga K – ident: e_1_2_30_2_6_1 doi: 10.4088/JCP.09m05866yel – volume: 4 start-page: CD003544 year: 2006 ident: e_1_2_41_2_43_1 article-title: Pharmacological treatments for psychosis‐related polydipsia publication-title: Cochrane Database Syst Rev contributor: fullname: Brookes G – ident: e_1_2_19_2_7_1 doi: 10.1016/j.schres.2006.09.013 – ident: e_1_2_22_2_3_1 doi: 10.4088/JCP.v63n0903 – ident: e_1_2_38_2_11_1 doi: 10.1016/S0006-3223(98)00312-6 – volume: 19 start-page: 21 year: 1999 ident: e_1_2_41_2_39_1 article-title: Effects of demeclocycline on psychiatric polydipsia in schizophrenic patients publication-title: Jpn J Pyschopharmacol contributor: fullname: Sanga M – ident: e_1_2_29_2_3_1 doi: 10.1192/bjp.151.5.634 – ident: e_1_2_42_2_72_1 doi: 10.1016/j.pnpbp.2004.05.016 – ident: e_1_2_42_2_48_1 doi: 10.1111/j.1600-0447.2009.01484.x – ident: e_1_2_24_2_5_1 doi: 10.1038/sj.npp.1300023 – ident: e_1_2_28_2_6_1 doi: 10.1038/npp.2010.111 – ident: e_1_2_18_2_25_1 doi: 10.1093/oxfordjournals.schbul.a033413 – ident: e_1_2_37_9_16_1 doi: 10.1016/j.pnpbp.2007.09.007 – ident: e_1_2_18_2_21_1 doi: 10.1016/j.schres.2007.10.022 – ident: e_1_2_43_2_5_1 doi: 10.1001/archpsyc.1989.01810100056011 – ident: e_1_2_44_2_24_1 doi: 10.2174/157340012798994867 – ident: e_1_2_21_4_5_1 doi: 10.3109/15622975.2012.696143 – volume: 15 start-page: 1841 year: 2012 ident: e_1_2_31_14_8_1 article-title: Usefulness of clozapine for treatment‐resistant schizophrenia in schizophrenia hospitalization programs publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Hashimoto R – volume: 4 start-page: CD003079 year: 2013 ident: e_1_2_37_9_35_1 article-title: Benzodiazepines for psychosis‐induced aggression or agitation publication-title: Cochrane Database Syst Rev contributor: fullname: Gillies D – ident: e_1_2_41_2_26_1 doi: 10.1046/j.1440-1819.2002.00937.x – ident: e_1_2_21_4_11_1 doi: 10.4088/JCP.v68n0301 – ident: e_1_2_34_2_9_1 doi: 10.1093/schbul/sbr004 – ident: e_1_2_44_2_36_1 doi: 10.1016/j.schres.2010.02.001 – ident: e_1_2_38_2_18_1 doi: 10.1097/yct.0b013e3181587949 – ident: e_1_2_23_2_12_1 doi: 10.1016/j.schres.2012.03.018 – ident: e_1_2_25_7_2_1 doi: 10.1016/j.schres.2011.11.021 – ident: e_1_2_22_2_23_1 doi: 10.1016/S0924-977X(96)00392-6 – ident: e_1_2_42_2_32_1 doi: 10.1093/schbul/sbq042 – ident: e_1_2_22_2_5_1 doi: 10.1001/archpsyc.60.7.681 – ident: e_1_2_17_2_4_1 doi: 10.1007/s00213-013-3241-3 – ident: e_1_2_17_2_10_1 doi: 10.4088/JCP.v67n1004 – ident: e_1_2_40_2_32_1 doi: 10.1016/j.schres.2006.03.037 – volume: 6 start-page: 1055 year: 2003 ident: e_1_2_41_2_23_1 article-title: A schizophrenia patient whose polydipsia improved after switching to perospirone publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Inada T – ident: e_1_2_37_9_8_1 doi: 10.1080/15622970903166312 – ident: e_1_2_40_2_20_1 doi: 10.1176/appi.ajp.2008.08060806 – ident: e_1_2_40_2_34_1 doi: 10.1037/1064-1297.15.6.563 – ident: e_1_2_41_2_4_1 doi: 10.3371/CSRP.4.2.3 – volume: 2 start-page: CD007778 year: 2009 ident: e_1_2_42_2_34_1 article-title: Chlorpromazine dose for people with schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Liu X – ident: e_1_2_18_2_4_1 doi: 10.1093/schbul/sbp116 – ident: e_1_2_33_2_12_1 doi: 10.1007/s00228-004-0835-z – ident: e_1_2_42_2_16_1 doi: 10.1017/S0033291799001476 – ident: e_1_2_44_2_14_1 doi: 10.1177/070674370605100310 – ident: e_1_2_38_2_17_1 doi: 10.1016/j.schres.2013.02.005 – volume: 27 start-page: 381 year: 1991 ident: e_1_2_43_2_9_1 article-title: Drug treatment of the neuroleptic malignant syndrome publication-title: Psychopharmacol Bull contributor: fullname: Sakkas P – ident: e_1_2_42_2_49_1 doi: 10.1093/schbul/21.3.431 – volume: 155 start-page: 751 year: 1998 ident: e_1_2_32_2_2_1 article-title: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome publication-title: Am J Psychiatry doi: 10.1176/ajp.155.6.751 contributor: fullname: Buchanan RW – volume: 47 start-page: 99 year: 1986 ident: e_1_2_41_2_32_1 article-title: Captopril in the treatment of psychogenic polydipsia publication-title: J Clin Psychiatry contributor: fullname: Goldstein JA – ident: e_1_2_33_2_8_1 doi: 10.3109/13651500903402450 – ident: e_1_2_42_2_52_1 doi: 10.1136/bmj.321.7273.1371 – ident: e_1_2_25_7_3_1 doi: 10.1001/archpsyc.56.3.241 – ident: e_1_2_42_2_64_1 doi: 10.1192/bjp.174.3.238 – ident: e_1_2_44_2_21_1 doi: 10.1176/appi.ajp.2007.07010079 – ident: e_1_2_33_2_42_1 – ident: e_1_2_42_2_79_1 doi: 10.1002/1531-8257(199907)14:4<652::AID-MDS1015>3.0.CO;2-G – ident: e_1_2_17_2_12_1 doi: 10.1080/15622970903166312 – ident: e_1_2_18_2_15_1 doi: 10.4088/JCP.v68n1113 – ident: e_1_2_32_2_16_1 doi: 10.1016/S0140-6736(09)60742-X – ident: e_1_2_30_2_4_1 doi: 10.1136/bmj.301.6756.837 – volume: 11 start-page: CD006633 year: 2010 ident: e_1_2_32_2_10_1 article-title: Clozapine versus other atypical antipsychotics for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Asenjo Lobos C – ident: e_1_2_16_3_3_1 doi: 10.2165/11314280-000000000-00000 – volume: 51 start-page: 357 year: 1990 ident: e_1_2_38_2_10_1 article-title: Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam publication-title: J Clin Psychiatry contributor: fullname: Rosebush PI – volume: 5 start-page: 343 year: 2002 ident: e_1_2_41_2_16_1 article-title: A case where quetiapine was effective against polydipsia publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Kajiyama H – ident: e_1_2_21_4_6_1 doi: 10.1177/0269881110391123 – volume: 15 start-page: 1213 year: 2012 ident: e_1_2_31_14_9_1 article-title: Case where blonanserin was effective due to a schizophrenia hospitalization program publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Yamaji K – volume: 14 start-page: 69 year: 2009 ident: e_1_2_41_2_22_1 article-title: A case of schizophrenia whose extent of work and polydipsia tendencies improved with orally disintegrating tablets of olanzapine publication-title: Jpn J Psychiatr Neurol contributor: fullname: Arai I – ident: e_1_2_24_2_6_1 doi: 10.1038/npp.2008.209 – ident: e_1_2_40_2_22_1 doi: 10.1016/j.pnpbp.2012.07.007 – ident: e_1_2_28_2_4_1 doi: 10.1056/NEJMoa1005987 – ident: e_1_2_21_4_19_1 doi: 10.1016/j.schres.2012.08.030 – ident: e_1_2_28_2_7_1 doi: 10.1192/bjp.bp.105.017020 – volume: 26 start-page: 91 year: 1990 ident: e_1_2_39_2_17_1 article-title: Adjunctive imipramine maintenance in post‐psychotic depression/negative symptoms publication-title: Psychopharmacol Bull contributor: fullname: Siris SG – ident: e_1_2_42_2_9_1 doi: 10.1176/ajp.154.9.1248 – ident: e_1_2_33_2_27_1 doi: 10.1176/appi.ajp.158.6.968-a – volume-title: Pharmacological therapy ident: e_1_2_37_9_18_1 contributor: fullname: Hatta S – ident: e_1_2_19_2_4_1 doi: 10.1016/j.psychres.2010.11.017 – ident: e_1_2_42_2_14_1 doi: 10.1016/S0149-2918(03)80129-7 – ident: e_1_2_36_2_21_1 doi: 10.1192/bjp.173.4.325 – ident: e_1_2_40_2_4_1 doi: 10.1093/oxfordjournals.schbul.a033430 – ident: e_1_2_22_2_30_1 doi: 10.4088/JCP.v65n1207 – ident: e_1_2_37_9_5_1 doi: 10.4088/JCP.v65n0315 – ident: e_1_2_42_2_5_1 doi: 10.1111/j.1440-1614.2004.01382.x – ident: e_1_2_37_9_6_1 doi: 10.1097/00131746-200607000-00004 – volume: 54 start-page: 439 year: 1993 ident: e_1_2_41_2_7_1 article-title: Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment publication-title: J Clin Psychiatry contributor: fullname: Munn NA – ident: e_1_2_22_2_19_1 doi: 10.1016/j.schres.2013.11.041 – ident: e_1_2_41_2_41_1 doi: 10.1056/NEJM197502202920803 – ident: e_1_2_22_2_24_1 doi: 10.1017/S0033291799001476 – ident: e_1_2_42_2_27_1 doi: 10.2165/00023210-200923070-00006 – ident: e_1_2_44_2_23_1 doi: 10.1176/appi.ajp.2012.11091432 – ident: e_1_2_31_14_2_1 – ident: e_1_2_39_2_2_1 doi: 10.1016/S0920-9964(00)00135-3 – ident: e_1_2_42_2_4_1 doi: 10.1111/j.1472-8206.1994.tb00808.x – ident: e_1_2_39_2_22_1 doi: 10.1097/00124509-200206000-00005 – ident: e_1_2_34_2_20_1 doi: 10.1111/j.1600-0447.2011.01792.x – ident: e_1_2_36_2_24_1 doi: 10.1176/appi.ajp.2011.10060908 – ident: e_1_2_23_2_11_1 doi: 10.1177/0004867413488221 – ident: e_1_2_41_2_38_1 doi: 10.1097/00002826-199619030-00007 – ident: e_1_2_18_2_16_1 doi: 10.4088/JCP.v68n1120 – ident: e_1_2_30_2_5_1 doi: 10.1016/j.schres.2011.11.021 – ident: e_1_2_40_2_5_1 doi: 10.1007/s00213-002-1342-5 – ident: e_1_2_27_2_3_1 doi: 10.2147/TCRM.S3153 – ident: e_1_2_43_2_16_1 doi: 10.1016/0165-1781(83)90059-8 – ident: e_1_2_44_2_35_1 doi: 10.1097/01.wnf.0000172994.56028.c3 – ident: e_1_2_42_2_13_1 doi: 10.1192/bjp.174.1.23 – ident: e_1_2_21_4_29_1 doi: 10.1097/JCP.0b013e31817e63a5 – ident: e_1_2_36_2_17_1 doi: 10.1097/00004850-200401000-00004 – volume: 27 start-page: 103 year: 1991 ident: e_1_2_22_2_16_1 article-title: Does sigma receptor antagonism predict clinical antipsychotic efficacy? publication-title: Psychopharmacol Bull contributor: fullname: Borison RL – ident: e_1_2_40_2_26_1 doi: 10.1016/j.pnpbp.2011.11.008 – ident: e_1_2_42_2_69_1 doi: 10.1001/archpsyc.1983.01790070083010 – ident: e_1_2_33_2_10_1 doi: 10.2165/00023210-200721010-00003 – volume: 45 start-page: 67 year: 1991 ident: e_1_2_42_2_89_1 article-title: Clinical variants of tardive dyskinesia in Japan publication-title: Jpn J Psychiatry Neurol contributor: fullname: Inada T – ident: e_1_2_42_2_7_1 doi: 10.1056/NEJM199709183371202 – ident: e_1_2_42_2_35_1 doi: 10.1001/archpsyc.1990.01810200069010 – ident: e_1_2_40_2_31_1 doi: 10.1097/YIC.0b013e3280117feb – ident: e_1_2_44_2_15_1 doi: 10.1016/j.schres.2007.03.029 – ident: e_1_2_41_2_37_1 doi: 10.2190/QPWL-14H7-HPGG-A29D – ident: e_1_2_33_2_11_1 doi: 10.4088/JCP.v67n0509 – volume-title: The Maudsley Prescribing Guidelines in Psychiatry year: 2012 ident: e_1_2_33_2_38_1 contributor: fullname: Taylor D – ident: e_1_2_22_2_22_1 doi: 10.1007/s002130050755 – ident: e_1_2_38_2_13_1 doi: 10.1111/j.1600-0447.1994.tb01515.x – ident: e_1_2_34_2_19_1 doi: 10.1097/YIC.0b013e3282fcff2f – ident: e_1_2_44_2_4_1 doi: 10.1016/0166-4328(96)00066-6 – ident: e_1_2_42_2_51_1 doi: 10.3310/hta7130 – volume: 5 start-page: CD001258 year: 2014 ident: e_1_2_24_2_7_1 article-title: Carbamazepine for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Leucht S – ident: e_1_2_33_2_9_1 doi: 10.1002/hup.1056 – ident: e_1_2_41_2_6_1 doi: 10.1097/00004714-199106000-00022 – ident: e_1_2_34_2_11_1 doi: 10.1177/0269881110372548 – ident: e_1_2_38_2_7_1 doi: 10.1007/PL00014198 – ident: e_1_2_37_9_31_1 doi: 10.1136/bmj.39341.608519.BE – ident: e_1_2_42_2_75_1 doi: 10.1192/bjp.145.3.304 – ident: e_1_2_27_2_2_1 doi: 10.1038/mp.2011.143 – ident: e_1_2_27_2_4_1 doi: 10.1016/j.schres.2007.08.002 – ident: e_1_2_39_2_8_1 doi: 10.1016/S0140-6736(08)61764-X – ident: e_1_2_41_2_42_1 doi: 10.1111/j.1600-0447.1988.tb06375.x – ident: e_1_2_44_2_37_1 doi: 10.1097/JCP.0b013e3182488758 – volume: 7 start-page: CD006196 year: 2013 ident: e_1_2_30_2_2_1 article-title: Intermittent drug techniques for schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Sampson S – ident: e_1_2_32_2_14_1 doi: 10.1016/S0278-5846(00)00118-4 – ident: e_1_2_38_2_16_1 doi: 10.2190/X0FF-VU7G-QQP7-L5V7 – ident: e_1_2_33_2_33_1 doi: 10.1016/j.schres.2009.05.007 – ident: e_1_2_42_2_66_1 doi: 10.1097/WNF.0b013e3181ee7f63 – ident: e_1_2_44_2_3_1 doi: 10.1038/374542a0 – ident: e_1_2_42_2_87_1 doi: 10.1097/00004714-199502001-00007 – ident: e_1_2_18_2_27_1 doi: 10.1097/01.jcp.0000115663.45074.8a – ident: e_1_2_36_2_15_1 doi: 10.1016/S0006-3223(00)01026-X – ident: e_1_2_37_9_17_1 doi: 10.1097/JCP.0000000000000050 – ident: e_1_2_34_2_13_1 doi: 10.1016/j.schres.2012.08.018 – volume: 13 start-page: 185 year: 2010 ident: e_1_2_41_2_13_1 article-title: A case where clozapine improved violence and polydipsia, as well as adherence publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Kawakami H – ident: e_1_2_39_2_11_1 doi: 10.1017/S0033291703007645 – ident: e_1_2_37_9_29_1 doi: 10.1016/j.eurpsy.2010.04.005 – volume: 19 start-page: 53 year: 1999 ident: e_1_2_42_2_17_1 article-title: Early phase II study of quetiapine fumarate on schizophrenia publication-title: Jpn J Pyschopharmacol contributor: fullname: Murasaki M – ident: e_1_2_19_2_8_1 doi: 10.4088/JCP.10m06349 – ident: e_1_2_42_2_10_1 doi: 10.1176/ajp.155.7.914 – ident: e_1_2_44_2_12_1 doi: 10.4088/JCP.v62n0204 – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_18_2_2_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_22_2_14_1 doi: 10.1097/JCP.0b013e3181d35d6b – ident: e_1_2_36_2_19_1 doi: 10.1093/schbul/sbn018 – volume: 40 start-page: 1193 year: 1989 ident: e_1_2_29_2_5_1 article-title: Neuroleptic dose reduction in persistently psychotic patients publication-title: Hosp Community Psychiatry contributor: fullname: Faraone SV – ident: e_1_2_32_2_29_1 doi: 10.1097/01.jcp.0000246215.49271.b8 – ident: e_1_2_20_2_5_1 doi: 10.1001/jamapsychiatry.2013.19 – ident: e_1_2_33_2_3_1 doi: 10.3109/00048674.2011.572852 – ident: e_1_2_40_2_35_1 doi: 10.1016/S0924-977X(02)00155-4 – ident: e_1_2_21_4_16_1 doi: 10.1097/JCP.0b013e3181d2193c – ident: e_1_2_40_2_23_1 doi: 10.1176/appi.ajp.161.1.116 – ident: e_1_2_28_2_8_1 doi: 10.1093/schbul/sbu067 – ident: e_1_2_42_2_26_1 doi: 10.1097/00004714-199706000-00010 – ident: e_1_2_41_2_5_1 doi: 10.1016/j.schres.2008.09.029 – ident: e_1_2_18_2_5_1 doi: 10.3109/15622975.2012.696143 – ident: e_1_2_21_4_22_1 doi: 10.2165/00003088-200342070-00001 – ident: e_1_2_32_2_13_1 doi: 10.4088/JCP.v69n0214 – ident: e_1_2_44_2_25_1 doi: 10.1038/npp.2010.21 – ident: e_1_2_26_2_4_1 doi: 10.1016/S0140-6736(09)60742-X – ident: e_1_2_34_2_16_1 doi: 10.1007/s002139900351 – ident: e_1_2_32_2_17_1 doi: 10.1002/pds.3567 – ident: e_1_2_32_2_19_1 doi: 10.1176/appi.ajp.158.8.1305 – ident: e_1_2_37_9_19_1 doi: 10.1136/bmj.327.7417.708 – ident: e_1_2_33_2_35_1 doi: 10.1016/j.schres.2010.02.1060 – ident: e_1_2_40_2_3_1 doi: 10.1176/ajp.153.3.321 – ident: e_1_2_40_2_28_1 doi: 10.1016/j.schres.2006.05.004 – ident: e_1_2_40_2_16_1 doi: 10.1093/oxfordjournals.schbul.a033374 – ident: e_1_2_39_2_4_1 doi: 10.1016/j.schres.2006.09.027 – volume-title: Clinical Manual of Electroconvulsive Therapy year: 2010 ident: e_1_2_35_2_4_1 contributor: fullname: Mankad MV – ident: e_1_2_38_2_9_1 doi: 10.3109/10401230009147094 – ident: e_1_2_42_2_30_1 doi: 10.1016/j.biopsych.2007.01.017 – ident: e_1_2_37_9_22_1 doi: 10.1016/S0735-6757(02)42249-8 – volume: 21 start-page: 97 year: 2003 ident: e_1_2_41_2_20_1 article-title: A case of schizophrenia which was discharged from the hospital for the first time in 19 years with additional administration of quetiapine publication-title: Pharma Medica contributor: fullname: Yamamura S – ident: e_1_2_42_2_67_1 doi: 10.4088/JCP.v65n1118 – ident: e_1_2_44_2_34_1 doi: 10.1177/0269881108089816 – ident: e_1_2_34_2_2_1 doi: 10.1176/appi.ajp.2014.13060787 – ident: e_1_2_21_4_25_1 doi: 10.1111/acps.12241 – ident: e_1_2_22_2_2_1 doi: 10.1097/JCP.0b013e318169d4ce – volume: 8 start-page: CD001951 year: 2013 ident: e_1_2_42_2_33_1 article-title: Haloperidol dose for the acute phase of schizophrenia publication-title: Cochrane Database Syst Rev contributor: fullname: Donnelly L – ident: e_1_2_34_2_5_1 doi: 10.1016/j.schres.2009.01.002 – volume: 4 start-page: CD001946 year: 2004 ident: e_1_2_42_2_61_1 article-title: Central action beta‐blockers versus placebo for neuroleptic‐induced acute akathisia publication-title: Cochrane Database Syst Rev contributor: fullname: Lima AR – ident: e_1_2_21_4_10_1 doi: 10.1097/01.jcp.0000246211.95905.8c – ident: e_1_2_23_2_4_1 doi: 10.4088/JCP.09m05154yel – ident: e_1_2_34_2_3_1 doi: 10.3923/pjbs.2007.4287.4290 – ident: e_1_2_43_2_6_1 doi: 10.1016/0140-6736(91)90138-F – ident: e_1_2_29_2_9_1 doi: 10.1176/appi.ajp.2009.09030358 – ident: e_1_2_36_2_4_1 doi: 10.4088/JCP.v66n0808 – ident: e_1_2_42_2_58_1 doi: 10.1192/bjp.149.1.42 – ident: e_1_2_42_2_81_1 doi: 10.1017/S1461145701002620 – ident: e_1_2_44_2_16_1 doi: 10.1016/j.schres.2009.05.007 – ident: e_1_2_39_2_19_1 doi: 10.1016/S0920-9964(99)00197-8 – ident: e_1_2_42_2_74_1 doi: 10.1097/jcp.0b013e318160864f – ident: e_1_2_19_2_5_1 doi: 10.1176/ajp.2006.163.4.743 – volume: 29 start-page: 1130 year: 2008 ident: e_1_2_44_2_13_1 article-title: A randomized, double‐blind, placebo‐controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents publication-title: Saudi Med J contributor: fullname: Arman S – ident: e_1_2_40_2_27_1 doi: 10.1016/j.jpsychires.2012.02.013 – ident: e_1_2_42_2_18_1 doi: 10.4088/JCP.v63n0903 – ident: e_1_2_33_2_34_1 doi: 10.1017/S1461145710000490 – ident: e_1_2_36_2_23_1 doi: 10.1017/S1461145703004012 – ident: e_1_2_38_2_8_1 doi: 10.1111/j.1600-0447.1996.tb09815.x – ident: e_1_2_17_2_13_1 doi: 10.1016/S0140-6736(08)60486-9 – ident: e_1_2_42_2_62_1 doi: 10.1097/00004714-198912000-00003 – ident: e_1_2_44_2_7_1 doi: 10.1016/S0140-6736(13)60733-3 – ident: e_1_2_37_9_9_1 doi: 10.1097/JCP.0b013e3181db8715 – ident: e_1_2_40_2_2_1 doi: 10.1016/S0006-3223(99)00152-3 – ident: e_1_2_35_2_9_1 doi: 10.1097/00124509-199909000-00002 – ident: e_1_2_32_2_5_1 doi: 10.1001/archpsyc.1996.01830120020005 – ident: e_1_2_40_2_33_1 doi: 10.2165/11530260-000000000-00000 – ident: e_1_2_37_9_37_1 doi: 10.1097/00004714-200002000-00018 – ident: e_1_2_21_4_28_1 doi: 10.1097/01.jcp.0000117422.05703.ae – ident: e_1_2_28_2_3_1 doi: 10.4088/JCP.13r08440 – ident: e_1_2_36_2_18_1 doi: 10.1093/schbul/sbp163 – ident: e_1_2_26_2_7_1 doi: 10.1016/j.schres.2011.11.021 – ident: e_1_2_43_2_13_1 doi: 10.1016/S0016-5085(77)80141-8 – ident: e_1_2_18_2_20_1 doi: 10.1016/S0140-6736(08)60486-9 – ident: e_1_2_29_2_6_1 doi: 10.1176/ajp.151.12.1753 – ident: e_1_2_41_2_8_1 doi: 10.1016/0006-3223(94)90089-2 – ident: e_1_2_37_9_23_1 doi: 10.1001/archpsyc.59.5.441 – ident: e_1_2_22_2_4_1 doi: 10.1016/j.jpsychires.2007.05.002 – volume: 175 year: 2014 ident: e_1_2_22_2_18_1 article-title: Examination of the effectiveness and safety of asenapine in acutely exacerbating schizophrenia patients publication-title: Japanese Society of Clinical Neuropsychopharmacology/Japanese Society of Neuropsychopharmacology Joint Annual Program/Abstracts contributor: fullname: Kinoshita T – ident: e_1_2_39_2_9_1 doi: 10.4088/JCP.09m05258gre – ident: e_1_2_33_2_37_1 doi: 10.2174/157488611797579230 – volume: 40 start-page: 1209 year: 1998 ident: e_1_2_41_2_11_1 article-title: A case of chronic schizophrenic patient whose polydipsia was improved by clozapine publication-title: Seishin Igaku contributor: fullname: Takada H – ident: e_1_2_43_2_8_1 doi: 10.1176/ajp.2007.164.6.870 – ident: e_1_2_42_2_2_1 doi: 10.3109/15622975.2012.739708 – ident: e_1_2_42_2_83_1 doi: 10.1192/bjp.156.3.412 – ident: e_1_2_23_2_6_1 doi: 10.1017/S1461145710000490 – ident: e_1_2_42_2_90_1 doi: 10.1016/0920-9964(95)00096-8 – volume-title: The Maudsley Prescribing Guidelines in Psychiatry year: 2012 ident: e_1_2_31_14_5_1 contributor: fullname: Taylor D – ident: e_1_2_18_2_29_1 doi: 10.1017/S1461145704004262 – ident: e_1_2_37_9_4_1 doi: 10.3109/15622975.2012.696143 – start-page: 1 volume-title: Neuroleptic Malignant Syndrome and Related Conditions year: 2003 ident: e_1_2_43_2_4_1 contributor: fullname: Caroff SN – volume-title: Clinical Manual of Electroconvulsive Therapy year: 2010 ident: e_1_2_31_14_6_1 contributor: fullname: Mankad MV – ident: e_1_2_36_2_13_1 doi: 10.1176/appi.ajp.159.2.255 – ident: e_1_2_25_7_5_1 doi: 10.1002/wps.20060 – volume: 36 start-page: 151 year: 2008 ident: e_1_2_37_9_7_1 article-title: Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study publication-title: Actas Esp Psychiatr contributor: fullname: Escobar R – ident: e_1_2_26_2_6_1 doi: 10.1097/JCP.0b013e31802dda4a – ident: e_1_2_37_9_2_1 doi: 10.1097/00131746-200511001-00002 – ident: e_1_2_22_2_7_1 doi: 10.1001/archpsyc.1997.01830180067009 – ident: e_1_2_34_2_7_1 doi: 10.1016/j.schres.2012.11.006 – ident: e_1_2_44_2_17_1 doi: 10.4088/JCP.12m08186 – ident: e_1_2_33_2_31_1 doi: 10.1136/bcr.09.2011.4790 – ident: e_1_2_21_4_18_1 doi: 10.1016/j.schres.2011.02.011 – volume: 46 start-page: 733 year: 1992 ident: e_1_2_42_2_63_1 article-title: Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double‐blind study publication-title: Jpn J Psychiatry Neurol contributor: fullname: Horiguchi J – ident: e_1_2_33_2_13_1 doi: 10.1089/104454603322572697 – ident: e_1_2_35_2_10_1 doi: 10.1097/WNF.0b013e31825e7945 – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_19_2_3_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_36_2_2_1 doi: 10.1016/j.biopsych.2004.06.029 – ident: e_1_2_36_2_8_1 doi: 10.1001/archgenpsychiatry.2011.1532 – ident: e_1_2_35_2_3_1 doi: 10.1016/j.schres.2013.02.005 – ident: e_1_2_39_2_16_1 doi: 10.4088/JCP.09m05699gre – ident: e_1_2_40_2_9_1 doi: 10.1016/j.pnpbp.2004.11.005 – ident: e_1_2_33_2_18_1 doi: 10.1097/00004850-199300810-00011 – ident: e_1_2_33_2_21_1 doi: 10.1177/2045125311405566 – volume: 18 start-page: 1339 year: 1989 ident: e_1_2_41_2_3_1 article-title: Polydipsia behavior in schizophrenic patients publication-title: Jpn J Clin Psychiatry contributor: fullname: Matsuda G – ident: e_1_2_20_2_4_1 doi: 10.4088/JCP.v68n0502 – ident: e_1_2_33_2_14_1 doi: 10.1097/00004850-199805000-00008 – ident: e_1_2_30_2_3_1 doi: 10.1136/bmj.298.6679.985 – ident: e_1_2_42_2_31_1 doi: 10.1002/gps.862 – ident: e_1_2_42_2_78_1 doi: 10.1016/0278-5846(95)00309-6 – ident: e_1_2_43_2_14_1 doi: 10.1212/WNL.40.9.1427 – ident: e_1_2_22_2_6_1 doi: 10.1016/S0006-3223(97)00190-X – volume: 1 start-page: 69 year: 1998 ident: e_1_2_41_2_25_1 article-title: Effects of risperidone on polydipsia and water intoxication in which an imbalanced state of DA2 and 5‐HT2 receptors is presumed publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Nakamura J – ident: e_1_2_32_2_3_1 doi: 10.1056/NEJM199709183371202 – ident: e_1_2_38_2_14_1 doi: 10.1097/00004714-199002000-00024 – ident: e_1_2_42_2_29_1 doi: 10.1016/j.schres.2006.09.012 – ident: e_1_2_40_2_10_1 doi: 10.1007/s00406-007-0739-x – ident: e_1_2_42_2_37_1 doi: 10.1159/000119254 – ident: e_1_2_37_9_14_1 doi: 10.4088/JCP.v68n0503 – ident: e_1_2_42_2_84_1 doi: 10.4088/JCP.v66n0907 – year: 2011 ident: e_1_2_21_4_30_1 article-title: A Systematic Review of Combination and High‐Dose Atypical Antipsychotic Therapy in Patients with publication-title: Schizophrenia contributor: fullname: CADTH – ident: e_1_2_39_2_7_1 doi: 10.1001/archpsyc.1995.03950130029004 – ident: e_1_2_42_2_28_1 doi: 10.1016/j.schres.2007.03.003 – ident: e_1_2_44_2_28_1 doi: 10.1002/hup.477 – ident: e_1_2_32_2_18_1 doi: 10.1001/archpsyc.60.1.82 – ident: e_1_2_36_2_20_1 doi: 10.1192/bjp.188.2.122 – ident: e_1_2_42_2_25_1 doi: 10.1056/NEJMoa002028 – ident: e_1_2_37_9_13_1 doi: 10.1097/JCP.0b013e31818aaf6c – ident: e_1_2_42_2_42_1 doi: 10.2165/00002018-199819010-00005 – ident: e_1_2_17_2_14_1 doi: 10.1093/schbul/sbs005 – ident: e_1_2_44_2_8_1 doi: 10.1016/j.schres.2008.09.031 – ident: e_1_2_37_9_21_1 doi: 10.1016/j.clinthera.2005.10.001 – volume: 57 start-page: 123 year: 1996 ident: e_1_2_41_2_10_1 article-title: Clozapine treatment in polydipsia and intermittent hyponatremia publication-title: J Clin Psychiatry contributor: fullname: Spears NM – volume: 29 start-page: 309 year: 1993 ident: e_1_2_21_4_2_1 article-title: Treatment of neuroleptic‐resistant schizophrenic relapse publication-title: Psychopharmacol Bull contributor: fullname: Kinon BJ – volume: 149 start-page: 506 year: 1992 ident: e_1_2_24_2_2_1 article-title: Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia publication-title: Am J Psychiatry contributor: fullname: Barbee JG – volume: 156 start-page: 294 year: 1999 ident: e_1_2_32_2_9_1 article-title: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response publication-title: Am J Psychiatry doi: 10.1176/ajp.156.2.294 contributor: fullname: Breier AF – ident: e_1_2_44_2_6_1 doi: 10.1017/S1461145712001277 – ident: e_1_2_33_2_30_1 doi: 10.2147/DMSO.S62681 – ident: e_1_2_33_2_17_1 doi: 10.1097/00004714-200306000-00002 – ident: e_1_2_21_4_4_1 – ident: e_1_2_44_2_29_1 doi: 10.1002/hup.514 – ident: e_1_2_42_2_22_1 doi: 10.1097/00004714-199302000-00004 – ident: e_1_2_21_4_26_1 doi: 10.4088/JCP.v69n0122e – ident: e_1_2_44_2_22_1 doi: 10.1001/jama.2007.56-b – ident: e_1_2_44_2_27_1 doi: 10.1590/S1516-44462006000400005 – ident: e_1_2_21_4_21_1 doi: 10.2165/00003088-199834030-00005 – ident: e_1_2_36_2_16_1 doi: 10.1016/j.pnpbp.2003.09.033 – ident: e_1_2_41_2_34_1 doi: 10.1016/0006-3223(90)90594-R – volume-title: Practice Guideline for the Treatment of Patients With Schizophrenia year: 2004 ident: e_1_2_31_14_3_1 contributor: fullname: American Psychiatric Association – ident: e_1_2_42_2_88_1 doi: 10.1097/JCP.0000000000000250 – ident: e_1_2_43_2_15_1 doi: 10.1007/BF00439271 – volume: 7 start-page: 23 year: 2010 ident: e_1_2_28_2_5_1 article-title: A Prospective Study Comparing the Long‐term Effectiveness of Injectable Risperidone Long‐acting Therapy and Oral Aripiprazole in Patients with Schizophrenia publication-title: Psychiatry (Edgmont) contributor: fullname: Macfadden W – ident: e_1_2_39_2_18_1 doi: 10.1016/0278-5846(92)90059-N – ident: e_1_2_43_2_18_1 doi: 10.1080/j.1440-1614.1999.00630.x – ident: e_1_2_28_2_2_1 doi: 10.1093/schbul/sbs150 – ident: e_1_2_37_9_11_1 doi: 10.1016/j.ajem.2004.02.021 – ident: e_1_2_43_2_20_1 doi: 10.1017/S1092852900013407 – ident: e_1_2_33_2_28_1 doi: 10.1176/appi.ajp.158.11.1930-a – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_39_2_6_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_17_2_5_1 doi: 10.1002/hup.2270 – ident: e_1_2_23_2_2_1 doi: 10.1093/schbul/sbn018 – ident: e_1_2_21_4_7_1 doi: 10.1001/archpsyc.60.12.1228 – ident: e_1_2_36_2_12_1 doi: 10.1016/S0006-3223(98)00291-1 – ident: e_1_2_23_2_8_1 doi: 10.2165/11587810-000000000-00000 – volume: 43 start-page: 37 year: 2010 ident: e_1_2_22_2_8_1 article-title: A failed 6‐week, randomized, double‐blind, placebo‐controlled study of once‐daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned publication-title: Psychopharmacol Bull contributor: fullname: Cutler AJ – ident: e_1_2_38_2_6_1 doi: 10.1007/s002130050904 – ident: e_1_2_23_2_10_1 doi: 10.1002/hup.1272 – volume: 7 start-page: 971 year: 2004 ident: e_1_2_41_2_31_1 article-title: Measures against polydipsia and water intoxication publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Ichie R – volume: 74 start-page: 29 year: 1991 ident: e_1_2_41_2_36_1 article-title: The successful treatment of psychogenic polydipsia and water intoxication with propranolol publication-title: Minn Med contributor: fullname: Goldstein MB – ident: e_1_2_18_2_18_1 doi: 10.1016/j.schres.2006.06.021 – ident: e_1_2_24_2_4_1 doi: 10.1097/00004714-200006000-00011 – volume: 17 start-page: 543 year: 2010 ident: e_1_2_41_2_24_1 article-title: Effectiveness of blonanserin for a schizophrenic patient with hyperprolactinemia and polyposia publication-title: Psychiatry contributor: fullname: Yamashita T – ident: e_1_2_33_2_36_1 doi: 10.1177/070674370705200607 – ident: e_1_2_40_2_19_1 doi: 10.4088/JCP.08m04634 – ident: e_1_2_32_2_23_1 doi: 10.1176/appi.ajp.162.5.1013 – ident: e_1_2_36_2_10_1 doi: 10.1097/00004850-200111000-00002 – ident: e_1_2_18_2_12_1 doi: 10.1176/appi.ajp.160.8.1396 – ident: e_1_2_37_9_38_1 doi: 10.1097/00004714-200106000-00002 – ident: e_1_2_17_2_7_1 doi: 10.1097/WNF.0b013e31817c6b06 – volume: 41 start-page: 11 year: 2008 ident: e_1_2_22_2_9_1 article-title: The efficacy and tolerability of once‐daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6‐week randomized, double‐blind, placebo‐controlled study publication-title: Psychopharmacol Bull contributor: fullname: Lindenmayer JP – ident: e_1_2_39_2_12_1 doi: 10.1097/00004850-200103000-00003 – ident: e_1_2_40_2_24_1 doi: 10.1016/j.pnpbp.2010.08.030 – ident: e_1_2_37_9_24_1 doi: 10.4088/JCP.v68n1207 – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_42_2_46_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_34_2_8_1 – ident: e_1_2_38_2_20_1 doi: 10.1080/15622970902718782 – volume: 44 start-page: 909 year: 2002 ident: e_1_2_41_2_17_1 article-title: A case of schizophrenia with polydipsia, positive symptoms, improved by quetiapine publication-title: Seishin Igaku contributor: fullname: Misawa H – ident: e_1_2_42_2_41_1 doi: 10.1097/00004714-199010060-00002 – ident: e_1_2_18_2_8_1 doi: 10.1016/j.schres.2013.04.014 – ident: e_1_2_40_2_21_1 doi: 10.1176/appi.ajp.162.10.1888 – ident: e_1_2_42_2_68_1 doi: 10.1097/00002826-200603000-00002 – ident: e_1_2_33_2_2_1 doi: 10.1192/bjp.169.4.483 – ident: e_1_2_33_2_7_1 doi: 10.1089/cap.2011.0136 – ident: e_1_2_38_2_19_1 doi: 10.4103/0019-5545.82544 – ident: e_1_2_42_2_59_1 doi: 10.1097/00004714-200112000-00013 – volume: 3 start-page: CD005146 year: 2009 ident: e_1_2_37_9_26_1 article-title: Haloperidol plus promethazine for psychosis‐induced aggression publication-title: Cochrane Database Syst Rev contributor: fullname: Huf G – ident: e_1_2_37_9_28_1 doi: 10.1016/S0165-1781(03)00107-0 – volume: 31 start-page: 93 year: 2006 ident: e_1_2_21_4_8_1 article-title: The “delayed onset” of antipsychotic action–an idea whose time has come and gone publication-title: J Psychiatry Neurosci contributor: fullname: Agid O – ident: e_1_2_21_4_20_1 doi: 10.1007/BF00215481 – ident: e_1_2_32_2_24_1 doi: 10.1177/026988110401800306 – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_16_3_2_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_33_2_19_1 doi: 10.1016/0140-6736(91)90410-Q – ident: e_1_2_32_2_26_1 doi: 10.1016/S0006-3223(00)01026-X – ident: e_1_2_18_2_9_1 doi: 10.1097/JCP.0b013e31827cb017 – ident: e_1_2_40_2_11_1 doi: 10.1007/s00406-007-0748-9 – ident: e_1_2_41_2_30_1 doi: 10.1093/schbul/22.3.455 – volume: 31 start-page: 2181 year: 1997 ident: e_1_2_42_2_21_1 article-title: Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia — Late‐phase II study publication-title: Clinical Report contributor: fullname: Murasaki M – ident: e_1_2_40_2_30_1 doi: 10.1017/S1461145703004024 – ident: e_1_2_38_2_2_1 – volume-title: Japan Diabetes Society (ed): Clinical guideline for diabetes based on scientific evidence 2013 year: 2013 ident: e_1_2_33_2_41_1 – volume: 13 start-page: 621 year: 2010 ident: e_1_2_41_2_14_1 article-title: A case of schizophrenia whose polydipsia improved with clozapine and was able to rehabilitate publication-title: Jpn J Clin Psychopharmacol contributor: fullname: Ichikawa R – volume: 161 start-page: 1 issue: 2 year: 2004 ident: e_1_2_21_4_3_1 article-title: Practice guideline for the treatment of patients with schizophrenia, second edition publication-title: Am J Psychiatry contributor: fullname: Lehman AF – ident: e_1_2_32_2_12_1 doi: 10.1001/archpsyc.63.7.721 – volume: 11 start-page: CD009377 year: 2012 ident: e_1_2_42_2_44_1 article-title: Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) publication-title: Cochrane Database Syst Rev contributor: fullname: Powney MJ – ident: e_1_2_18_2_7_1 doi: 10.1097/JCP.0b013e3182825c1e – ident: e_1_2_21_4_9_1 doi: 10.1176/appi.ajp.160.11.2063 – ident: e_1_2_29_2_11_1 doi: 10.1016/j.schres.2011.11.021 – ident: e_1_2_44_2_10_1 doi: 10.2147/TCRM.S3153 – ident: e_1_2_21_4_12_1 doi: 10.4088/JCP.v68n1008 – ident: e_1_2_22_2_27_1 doi: 10.1097/00004714-199808000-00009 – ident: e_1_2_18_2_24_1 doi: 10.4088/JCP.v63n1006 – ident: e_1_2_32_2_27_1 doi: 10.1136/bmj.38881.382755.2F – ident: e_1_2_37_9_20_1 doi: 10.1192/bjp.185.1.63 – ident: e_1_2_36_2_5_1 doi: 10.1097/00004850-200203000-00003 – ident: e_1_2_36_2_14_1 doi: 10.1176/ajp.155.4.499 – ident: e_1_2_37_9_10_1 doi: 10.1186/1471-244X-13-20 – start-page: 313 volume-title: Yamaguchi Hospital Pharmacists Association (ed): Checking Manual for Dispensing Injectable Drugs year: 2012 ident: e_1_2_37_9_34_1 contributor: fullname: Ishimoto K – ident: e_1_2_36_2_7_1 doi: 10.1016/j.euroneuro.2013.03.001 – ident: e_1_2_39_2_5_1 doi: 10.1111/j.1600-0447.2010.01608.x – ident: e_1_2_40_2_29_1 doi: 10.1016/S0006-3223(01)01342-7 |
| SSID | ssj0002000234 |
| Score | 2.3414323 |
| Snippet | English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health,... |
| SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 266 |
| SubjectTerms | Guidelines Guidelines as Topic Hospitals Humans Illnesses Japan Medicine Patients Pharmaceutical industry Psychiatry Psychopharmacology Public speaking Schizophrenia Schizophrenia - drug therapy Societies |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB6hnrggfgoECnIF6gE16saxE5tbiyhVD9UKWqk3K_4T7SG7aruH3vog8HJ9EmbsdJsVCC7crNhynJlx5ht55jPA--hCjFI3iNyCL0UXY2mlcmXQnY_WOy1dyrY4ag5OxOGpPB1d9UU5YZkeOAtux7ciEuUJIRWhrFPCBt-6rrNaRhty6V4lR8HUeTpeI2cklnykfKefX3CiUtD1igdKRP1_Qpe_J0mOwWvyPvuP4dEAG9luXu4TeBD6p7A1zbzT19vs-L6M6nKbbbHpPSP19TM4O0SXSFdNsiFJk80iS7QcuQhrPhr9kd3e_PiyIPYrBKAMMe14MlLp8LI0ybdxzt7tzc91ONn_fPzpoBzuWChdQwfvxEbjvLRtEDxMnHNt4ytsquCU8kGp2mEAgj-hJgYeYqVFh8JvnI5RVbXy9XNY62d9eAmss420XLuWGOsrX2sRJhw1FDoRqLy3gHd3cjfzTKVhMmkyN6Qdk7RTwB6pZDmC6K_TAzQKMxiF-ZdRFLBxp1Az7MlLw4lrTXLEhwVsLrtxN9ERCSphtkhjMGScIAos4EXW_3IlNWI3NCpeQLtiGStLXe3pz74nxm4lKoz6qwI-JBv6y-ebo-lXnlqv_ocgXsNDTkk4KSluA9auLhbhDaKoK_s2bZhfzGohgQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VVkJcEJRX2oKMQD2gRrtxnMTmgihqWVWiWkEr9WbFr9JLsmx3D731h8Cf6y_B43izuwL1ZiWWH5oZz2fP-DPAe6etc4UoPXKzJmW1c6kquE6tqI1TRotCh2yL03J0zk4uiosNGC3uwmBa5WJNDAu1aTWekQ8oMmUV1Hv3Qa3wFEDPBp8mv1J8PwrjrPExjQewRTOGAdutw6PT8ff-vIUGahfWM5TSQTOZUiRXEPmaTwrU_f_Dm_-mTa7C2eCPjp_A4wgkyedO8k9hwzbb8PBbDJVvw_64I6W-OSBnyztW1wdkn4yXdNU3z-DqxPtLfIeSxAxO0joSODu6G1qTldofyd3t769zpMbynRAPeFcbQ3nHzkIjP1YT-u5u_zyH8-Ojsy-jND7AkOoSo_JIVaNNoSrLqB1qravSZL7IrebcWM5z7XcnfoUqnaXWZYLVla5LLZzjWc5N_gI2m7axr4DUqiwUFbpCOvvM5ILZIVVW2JpZvPubwLuFCOSk49mQHaMylSgoGQSVwCFKp6-B3NjhQzu9lNHUpKmYQ5IcxLaMK82ZssaPq1aicL7LBPYWspXRYK_lUr0SeNv_9qaG8RMvhHYe6vj95NBDxARedqrQjyT3wM7rF02gWlOStaGu_2mufgY6b86yLKdZAh-COt0zfekVmobSzv1z2IVHFHNvQi7cHmzOpnP72oOnmXoT7eIvqesgVg priority: 102 providerName: ProQuest – databaseName: Wiley Online Library dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3NbtQwEMdHpVx6QeWjJaUgI1APVaNuHCexERdAlKqHakVbaW9W_AW97K52u4fe-iDwcn0SZpxsNisqJG5R4iROZib-2x7_AvA-WB9CoUpUbt6log4hNYW0qVe1C8ZZVdiYbXFenl6Js1Ex2oCPy7UwDR-iG3CjyIjfawrw2syPe9DQ6YwTG0Hlj-Ax6hpJPs3FsBth4RHmQtPK6JYizap81PFJ-fHq9LUWKYL7H1KbfydN9sVsbI1OtuFJKyPZp8buT2HDj5_BwbDhUN8escvVsqr5ETtgwxWh-vY5XJ9hE0m_nmRt0iabBBYxHc2irGmv9Ad2f_fr24JoWPjKGGrc_sXIxO3N4kUu-jl893e_X8DVydfLL6dp-8-F1JY0EU90GusKU3nB_cBaW5Uuw03prZTOS5lb7JDgR6kMnvuQKVFXti6tCkFmuXT5DmyOJ2P_ElhtysJwZSsi2GcuV8IPuPHK18LTct8E3i3fu542aA3dQJS5JuvoaJ0EPpNJuhKEw447JrMfuo0u7SoRiItDclZIY6Uw3mG9aqOKgLdMYH9pUN3G6FxzYq8VHPViAm-7wxhdNGWCRpgsYhnsQg5QFSaw29i_q0mOWg4djCdQrXnGWlXXj4yvf0aCtxRZlvMsgcPoQ_94fH0-_M7j1t7_FH4FW5ySb2Iy3D5s3swW_jWqpxvzJgbJH28IGt0 priority: 102 providerName: Wiley-Blackwell |
| Title | Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia” |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fnpr2.12193 https://www.ncbi.nlm.nih.gov/pubmed/34390232 https://www.proquest.com/docview/2568152435/abstract/ https://search.proquest.com/docview/2561490600 https://pubmed.ncbi.nlm.nih.gov/PMC8411321 https://doaj.org/article/d74f4564139748bc84bed7caab95fbe9 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9MwGH61jgsXxPgMjMoItANa1sZxEpvbOlamSUwRbFJvUfw1ilhadetht_2Q8ef2S3jtJF0qEAcuSRRbtpP3dd7H8ePHAO-tMtYmIkXkZnTISmtDmXAVGlFqK7USifJsi5P06IwdT5LJBiTtWhhP2ldyulf9vNirpt89t3J-oQYtT2yQfzngzO2PHg160MviuDNE_-Fn1lwcYispUjqo5gvqVBSE2zQnxgiM6XQtDnm5_r9hzD-pkl0I62PQ-DE8asAj2a8buQUbpnoCO3mtPn29S07vF1Nd7pIdkt_rUl8_hekxBka34SRpqJpkZokX56iXYs07uT-Su5vbz0ungYUwlCCy7RbmDNtU5gv51mXu3d38egZn48PTg6Ow2WkhVKmbfneaNEonMjOMmqFSKkt1hJfcKM614TxWOAzBT1FqDTU2EqzMVJkqYS2PYq7j57BZzSrzEkgp00RSoTKnWx_pWDAzpNIIUzLjFvkG8K5978W8FtQoaulkWjhDFd5QAYycSVY5nAi2vzFbnBeNKxQ6Y9ap4TgQy7hUnEmjsV2lFInFKgPYbg1aND3zsqBOcS2hiBIDeLtKxj7lJkrQCLOlz4MDxyFiwQBe1PZftaT1nwCyNc9Ya-p6Crqx1-1u3DaAD96H_vH4xUn-lfqrV_9dzWt4SB3_xvPhtmHzarE0bxBAXck-9CjL8ZhNsj482B99Go3xPDrEWvv-p0Tfd6nfDLYmmQ |
| link.rule.ids | 230,315,733,786,790,870,891,2115,11589,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,46087,46511,50849,50958,53827,53829,74102,74659 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkYALgvIKFDAC9YAadeM4ic0FAaIspV2tYCvtzYpf0Euy7HYPvfWHwJ_rL8HjeF8C9WYllh-aGfuzZ_wNwGunrXOFKD1ysyZltXOpKrhOraiNU0aLQodoi0HZP2GH42IcL9xmMaxysSaGhdq0Gu_I9ykyZRXU7-7vJr9SzBqF3tWYQuM63GB5zjCkrxpXyzsWGuhc2JKVlO43kylFQgWRb-xDga7_fxjz31DJdQgb9qCDu3AngkfyvpP2Pbhmm224eRzd49uwO-yIqM_3yGj1rmq2R3bJcEVRfX4fTg_9Hom5J0mM2iStI4Gno3uVNVmr_ZZcXvz-PEc6LN8J8SB3vTGUcewsNPJ9PYjv8uLPAzg5-DT62E9j0oVUl-iJR3oabQpVWUZtT2tdlSbzRW4158Zynmt_IvGrUukstS4TrK50XWrhHM9ybvKHsNW0jX0MpFZloajQFVLYZyYXzPaossLWzOJ73wReLUQgJx23huxYlKlEQckgqAQ-oHSWNZAPO3xopz9kNC9pKuaQGAfxLONKc6as8eOqlSic7zKBnYVsZTTSmVypVAIvl7-9eaHPxAuhnYc6_gzZ87AwgUedKixHknsw5_WLJlBtKMnGUDf_NKc_A4U3Z1mW0yyBN0Gdrpi-HAy_0VB6cvUcXsCt_uj4SB59GXx9Crcpxt6EWLgd2Dqbzu0zD57O1PNgIX8BKdkeIw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkSouCMqjgQJGoB5Qo904TmJzQbyWUmC1glbamxW_oJdk2e0eeusPgT_XX4LH8b4E6i1KrNjRzHi-2J-_AXjhtHWuEKVHbtakrHYuVQXXqRW1ccpoUejAthiWhyfsaFyMI_9pFmmVizkxTNSm1bhG3qOolFVQn917LtIiRu8Hrye_UqwghTutsZzGdbjhs2QfqxlU42q53kKDtAtbKpTSXjOZUhRXEPlGTgrS_f_Dm__SJtfhbMhHg9twKwJJ8qaz_B24Zpsd2P4at8p3YH_UiVKfH5Dj1Rmr2QHZJ6OVXPX5XTg98vkS61CSyOAkrSNBs6M7oTVZa_2KXF78_jhHaSzfCfGAd_1laO_YWXjJ93VC3-XFn3twMvhw_O4wjQUYUl3irjxK1WhTqMoyavta66o0mb_kVnNuLOe59n8nfoYqnaXWZYLVla5LLZzjWc5Nfh-2mraxu0BqVRaKCl2hnH1mcsFsnyorbM0snv1N4PnCBHLS6WzITlGZSjSUDIZK4C1aZ9kCtbHDjXb6Q8ZQk6ZiDkVyENsyrjRnyho_rlqJwvkuE9hb2FbGgJ3JlXsl8Gz52Ica7p94I7Tz0Mb_T_Y9REzgQecKy5HkHth5_6IJVBtOsjHUzSfN6c8g581ZluU0S-BlcKcrPl8OR99ouHp49Tc8hW0fHPLLp-HnR3CTIg0n0OL2YOtsOrePPY46U09CgPwFRpkiTw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Japanese+Society+of+Neuropsychopharmacology%3A+%22Guideline+for+Pharmacological+Therapy+of+Schizophrenia%22&rft.jtitle=Neuropsychopharmacology+reports&rft.date=2021-09-01&rft.eissn=2574-173X&rft.volume=41&rft.issue=3&rft.spage=266&rft_id=info:doi/10.1002%2Fnpr2.12193&rft_id=info%3Apmid%2F34390232&rft.externalDocID=34390232 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-173X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-173X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-173X&client=summon |